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ABSTRACT 
 
WILLIE WILSON III:  Regulation of Constitutive NF-κB Activity in Pancreatic Cancer by 
Glycogen Synthase Kinase-3 
(Under the direction of Dr. Al Baldwin) 
 
     The development of pancreatic cancer chemotherapy has evolved into targeting the 
complex signaling pathways associated with disease progression.  Recent focus has been 
made on targeting the constitutive activation of the transcription factor, NF-κB.  However, 
advancement of this therapeutic strategy is dependent on fully understanding the elusive 
mechanisms underlying constitutive NF-κB activity in pancreatic cancer.  Glycogen synthase 
kinase-3 has previously been implicated in regulating pro-survival NF-κB signaling in 
pancreatic cancer cells through an unknown mechanism.  Moreover, TGF-β activated kinase 
1 (TAK1) is a known regulator of NF-κB activity in human cancers, but its role in pancreatic 
cancer has yet to be established.  In this report, we characterize GSK-3-dependent NF-κB 
regulation in pancreatic cancer cells and provide initial evidence that GSK-3 facilitates 
constitutive IκB kinase (IKK) activity.  Our data also indicates that TAK1 is active in 
pancreatic cancer and contributes to constitutive NF-κB activation.  Importantly, GSK-3 may 
be functionally linked to IKK through the phosphorylation of TAK1 at serine 412.   
Collectively, we propose that constitutive NF-κB activity in pancreatic cancer cells is 
maintained by a novel GSK-3-TAK1-IKK signaling cascade.  These data broadens our 
understanding of NF-κB regulation in pancreatic cancer and implicates GSK-3 and TAK1 as 
emerging therapeutic targets. 
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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1  Summary 
 
     The development of pancreatic cancer is characterized by the accumulation of various 
oncogenic mutations which leads to the deregulation of key signaling pathways (Sarkar, 
Banerjee et al. 2006).  The constitutive activation of the transcription factor, NF-κB, is 
among the many deregulated signaling pathways that have been associated with multiple 
malignancies, including pancreatic cancer (Sarkar, Banerjee et al. 2006).  Consequently, 
there has been focus on targeting constitutive NF-κB activity in pancreatic cancer (Zhang 
and Rigas 2006; Holcomb, Yip-Schneider et al. 2008).  Advancement of this therapeutic 
strategy is dependent on fully understanding the complex signaling events that drive NF-κB 
activity.  Here I provide new insight into the elusive signaling events that drive constitutive 
NF-κB activity in pancreatic cancer and discuss glycogen synthase kinase-3 (GSK-3), TGF-β 
activated kinase-1 (TAK1), and IκB kinase (IKK) as potential therapeutic targets that can be 
utilized to disrupt this pathway.  The following will provide a general overview of inducible 
NF-κB signal transduction and evidence of regulation by GSK-3 and TAK1.  Furthermore, I 
will review the functional significance of constitutive NF-κB activity during carcinogenesis 
and discuss the relevance to target this pathway in pancreatic cancer.   
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1.2 Pancreatic Ductal Adenocarcinoma 
     Pancreatic ductal adenocarcinoma (PDA) is the most common malignancy of the pancreas 
and is the fourth leading cause of cancer related deaths in the United States (Jemal, Siegel et 
al. 2008).  Approximately 37,680 new cases of pancreatic cancer will be expected in 2008, 
while 34,290 patients are estimated to die from this disease (Jemal, Siegel et al. 2008).  Poor 
early detection methods, aggressive metastatic potential, and chemotherapy resistance all 
account for the dismal mortality rate associated with pancreatic cancer.  The nucleoside 
analog, gemcitabine, is among the most active single-agent chemotherapy currently used to 
treat advanced stages of pancreatic cancer and is considered to be the first-line therapy for 
patients (Burris, Moore et al. 1997; Abbruzzese 2002).  Despite these efforts, the overall 5-
year survival rate for patients with pancreatic cancer still remains at 5% (Jemal, Siegel et al. 
2008).   Therefore, it is critical to advance our understanding of the molecular pathogenesis 
of pancreatic cancer in order to develop more targeted chemotherapies to treat this disease.   
     Extensive histological and genetic studies have characterized the pathogenesis of 
pancreatic cancer into three early stages of pre-invasive lesions known as pancreatic 
intraepithelial neoplasia (PanIN) (Fig. 1.1) (Hruban, Adsay et al. 2001; Kern, Hruban et al. 
2001).  The following PanINs are characterized by increasing degrees of architectural and 
nuclear atypia: low-grade PanIN1A and PanIN1B, intermediate grade PanIN2, and high-
grade PanIN3 (Fig. 1.1). Various genetic alterations are known to accumulate throughout the 
progression of PanIN lesions giving rise to invasive ductal adenocarcinoma (Fig 1.1).   These 
mutations include activation of proto-oncogenes (i.e. KRAS, AKT2, and HER2/ neu) and the 
inactivation of tumor suppressors (i.e. p16/CDKN2A, TP53, DPC4/SMAD4, BRCA2, and 
LKB1) (Table 1.1).  KRAS, p16/CDKN2A, and TP53 are invariably among the most 
 3
frequently mutated genes associated with human pancreatic cancers (Table 1.1) (Hruban, van 
Mansfeld et al. 1993; Redston, Caldas et al. 1994; Schutte, Hruban et al. 1997). 
     Recent advances in pancreatic cancer mouse models have revealed that these genetic 
events arise at distinct stages during the progression of PanIN lesions (Fig. 1.1). Gain-of-
function point mutation in KRAS at codon 12 (G12V or G12D) occur early during tumor 
development and is considered to be the initiating genetic event in precursor PanIN1 lesions 
(Moskaluk, Hruban et al. 1997).  Moreover, endogenous expression of KRAS G12D in mouse 
pancreas progenitor cells induced early PanIN lesions which progressed into invasive ductal 
adenocarcinoma (Hingorani, Petricoin et al. 2003).  Intermediate PanIN2 lesions are 
characterized by mutations, homozygous deletion, and promoter hypermethylation of the 
p16/CDKN2A locus (Moskaluk, Hruban et al. 1997; Schutte, Hruban et al. 1997; Wilentz, 
Geradts et al. 1998).  Furthermore, inactivation of the TP53 and DPC4/SMAD4 loci by loss-
of-heterozygosity (LOH) or homozygous deletion are frequently observed later during tumor 
progression in PanIN3 lesions (Redston, Caldas et al. 1994; Rozenblum, Schutte et al. 1997).  
     Taken together, there has been significant advancement in our understanding of the 
genetic alterations that initiate and drive PanIN lesions into advanced ductal 
adenocarcinomas.  As a result, new insight has emerged in comprehending the network of 
deregulated signal transduction pathways associated with pancreatic cancer.   For example, 
constitutive signaling from PI3K/Akt, EGFR, COX-2, and Ras/Raf/MAPK pathways have all 
been implicated to play key roles in the development and progression of pancreatic cancers 
(Sarkar, Banerjee et al. 2006).  Interestingly, these deregulated pathways utilize molecular 
crosstalk with the transcription factor, NF-κB (Sarkar, Banerjee et al. 2006). Thus, focus has 
been on targeting constitutive NF-κB signaling as an alternative therapeutic strategy to treat 
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pancreatic cancer (Holcomb, Yip-Schneider et al. 2008).  However, advancement of this 
strategy is dependent on fully understanding the signaling events that drive constitutive NF-
κB activation.    
     
1.3  NF-κB Signal Transduction 
 
     NF-κB was originally discovered over 20 years ago as a nuclear factor that binds the 
immunoglobulin κ enhancer sequence in B-cells (Sen and Baltimore 1986).  NF-κB has since 
been characterized as an inducible family of conserved dimeric transcription factors 
consisting of: RelA/p65, RelB, c-Rel, p52 (p100 precursor), and p50 (p105 precursor) (Fig. 
1.2).  NF-κB exists in cells as homo- or heterodimers and can function to either promote or 
repress gene transcription.  The most studied NF-κB complex consists of the p65/p50 
heterodimer (Ghosh, May et al. 1998).  Figure 1.2 illustrates the domain organization of the 
NF-κB family members.  The N-terminal region of NF-κB consists of a highly conserved, 
300 amino-acid, Rel homology domain (RHD) which promotes dimerization, nuclear 
localization, and DNA binding.  A C-terminal transactivational domain (TAD) is located 
within RelA/p65, RelB, and c-Rel and facilitates NF-κB transcriptional activity upon 
inducible posttranslational modifications.  Phosphorylation of RelA/ p65 at serines 536 
(Mattioli, Sebald et al. 2004), 468 (Mattioli, Geng et al. 2006), and 276 (Zhong, Voll et al. 
1998) has been reported to promote NF-κB transcriptional activity (Fig. 1.2).  The C-terminal 
region of the precursor NF-κB members (p100 and p105) contains an inhibitor ankyrin repeat 
domain which functions to mask the nuclear localization sequence of NF-κB.  This domain 
can undergo proteolytic cleavage, thus generating the mature p52 and p50 subunits.  
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Although processing of p105 to p50 is known to be constitutive, p100 to p52 processing is 
tightly regulated (Xiao, Harhaj et al. 2001).   
     The inducible activity of NF-κB has been extensively studied since its discovery and has 
been shown to play a central role in the regulation of diverse biological processes such as 
inflammation, immunity, development, cell proliferation, and survival (Ghosh and Karin 
2002).  The NF-κB target genes that drive these biological processes include cytokines (i.e. 
IL-6, IL-12 TNF-α, and LTβ), chemokines (i.e. MCP1, IL-8, RANTES, and MIP-1α) , and 
adhesion molecules (i.e. ICAM and VCAM) (Ghosh and Karin 2002).  The signaling events 
that regulate NF-κB-dependent gene expression can be classified into two pathways: 
canonical and non-canonical (Fig. 1.3).   
     In resting cells, NF-κB is rendered inactive and sequestered in the cytoplasm through 
interaction with an inhibitor protein called IκB.  IκB represents a family of conserved 
proteins (IκBα, IκBβ, IκBε) which contain the aforementioned ankyrin repeat domain (Fig. 
1.4B).  Canonical NF-κB activity can be triggered by various stimuli including inflammatory 
cytokines, microbial infection, DNA damage, and mitogens (Pahl 1999).  These stimuli 
promote the activation of the IκB kinase (IKK) complex which consists of a regulatory 
subunit (IKKγ) and two catalytic, serine/ threonine kinase subunits (IKKα and IKKβ).  The 
domain organization of the IKK family members are illustrated in Figure 1.4A.  Once this 
complex is activated, IKKβ phosphorylates NF-κB-bound IκB proteins which leads to its 
rapid ubiquitination and subsequent proteasomal degradation (Delhase, Hayakawa et al. 
1999; Karin and Ben-Neriah 2000).  Consequently, NF-κB can undergo nuclear translocation 
and bind to κB consensus sequences within target gene promoters.   
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     Alternatively, non-canonical NF-κB signal transduction involves processing of the IκB-
like p100 precursor (Fig. 1.3B).  Prior to stimulation, RelB-containing NF-κB complexes are 
sequestered in the cytoplasm through interaction with p100.  Diverse stimuli such as 
lymphotoxin (LTα, LTβ), B-cell activating factor (BAFF), CD40 ligand, tumor necrosis 
factor (TNF)-like weak inducer of apoptosis (TWEAK), and RANKL trigger a signaling 
cascade which activates the NF-κB inducing kinase (NIK) (Xiao, Rabson et al. 2006).  NIK 
drives the activation of IKKα homodimers and their association with p100 NF-κB complexes 
(Bonizzi and Karin 2004).  Notably, non-canonical NF-κB activation is independent of the 
canonical IKK complex (Senftleben, Cao et al. 2001) (Fig. 1.3B).  IKKα subsequently 
phosphorylates p100, thereby leading to proteolytic processing and the generation of p52.  As 
a result, activated RelB/p52 heterodimers can translocate to the nucleus to drive NF-κB-
dependent gene transcription.   
     IKKα and IKKβ play pivotal roles in regulating the diverse pathways that lead to NF-κB 
activation.  Despite structural and sequence similarities, IKKα and IKKβ have distinct, non-
overlapping substrate specificities (Lee and Hung 2008).   In addition to IκB, IKKβ also 
phosphorylates p65 at serine 536 which promotes nuclear translocation and enhanced NF-κB 
transactivation (Mattioli, Sebald et al. 2004).  Moreover, NF-κB nuclear translocation can be 
mediated by IKKβ-dependent phosphorylation and subsequent proteolysis of p105 
(Salmeron, Janzen et al. 2001). Contrary to IKKβ, IKKα possesses the unique ability 
translocate to the nucleus upon cytokine stimulation (Anest, Hanson et al. 2003).  This 
function enables IKKα to target nuclear substrates required for NF-κB activation at target 
gene promoters.  Nuclear IKKα has been shown to modulate chromatin structure at a subset 
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of NF-κB target genes by interacting with cyclic AMP-responsive binding protein (CBP), 
and phosphorylating histone H3 at serine 10 (Anest, Hanson et al. 2003; Yamamoto, Verma 
et al. 2003).  Furthermore, IKKα also mediates the derepresssion of select NF-κB-responsive 
genes by promoting the phosphorylation and subsequent nuclear export of the co-repressor 
complex, SMRT (Hoberg, Yeung et al. 2004).  Overall, IKKα and IKKβ can play distinct 
physiological roles in modulating various stages of NF-κB activity during an inflammatory 
response.   
     The complex signaling that modulates NF-κB activity must be tightly regulated in order to 
maintain normal physiological homeostasis. Notably, the deregulation of this process has 
linked NF-κB to chronic inflammatory diseases (i.e. rheumatoid arthritis and lupus) and 
tumorigenesis (Karin and Greten 2005; Okamoto 2006).   There has been growing interest 
over the years in understanding the elusive mechanisms that drive NF-κB activity in 
pancreatic cancer and other human malignancies. The following section will review 
constitutive NF-κB signaling associated with cancer and therapeutic strategies currently 
being investigated to target NF-κB activity. 
 
1.4 Constitutive NF-κB Signaling in Cancer 
     Chronic inflammation was first suspected to promote the development of cancer in the 
nineteenth century by one of the founding fathers of modern pathology, Rudolf Virchow 
(Balkwill and Mantovani 2001).  Decades later, NF-κB was implicated to be the missing link 
between chronic inflammation and cancer (Karin, Cao et al. 2002).  Since then, constitutive 
NF-κB activity has become well accepted as one of the many hallmarks of carcinogenesis.  
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Constitutive NF-κB activation can be observed in human tumor samples, as well in, various 
cancer cell lines.  Breast cancer (Chua, Bhat-Nakshatri et al. 2007), colon cancer (Scartozzi, 
Bearzi et al. 2007), lung cancer (Tew, Lorimer et al. 2008), melanoma (Yang, Pan et al. 
2007), multiple myeloma (Annunziata, Davis et al. 2007), esophageal adenocarcinoma (Izzo, 
Malhotra et al. 2007), and pancreatic cancer (Weichert, Boehm et al. 2007) are among the 
many human malignancies that have been demonstrated to have constitutive NF-κB activity.  
Advancements in cancer mouse models have provided additional evidence connecting NF-
κB activity with the deregulated cellular processes associated with cancer (Naugler and Karin 
2008).  These processes include angiogenesis, metastasis, cell survival, cell cycle 
progression, and insensitivity to growth inhibition (Hanahan and Weinberg 2000).  
     The field of cancer research has made progress in understanding the molecular 
mechanism that drives the deregulation NF-κB activity.  Evidence suggests IKK plays a 
central oncogenic role in regulating constitutive NF-κB activation in various human cancers 
(Lee and Hung 2008).   Constitutive IKK activity has been implicated in breast cancer 
(Romieu-Mourez, Landesman-Bollag et al. 2001), prostate cancer (Gasparian, Yao et al. 
2002), diffuse large B-cell lymphoma (DLBCL) (Lam, Davis et al. 2005), multi-drug 
resistant leukemias (Garcia, Alaniz et al. 2005) and pancreatic cancer (Liptay, Weber et al. 
2003).  The genetic ablation of IKK in cancer mouse models has also established a critical 
role for IKK during carcinogenesis.  For instance, the deletion of IKKβ in enterocytes 
significantly reduces tumor formation in a mouse model of colitis-associated cancer (Greten, 
Eckmann et al. 2004).  Moreover, a Neu/ErbB2-driven breast cancer mouse model was 
shown to undergo significant growth suppression upon the genetic introduction of an inactive 
 9
IKKα mutant (Cao, Luo et al. 2007).  Collectively, these reports and others underscore the 
need to target IKK and NF-κB as a chemotherapeutic strategy. 
     Cancer researchers have improved their ability to identify the chemotherapeutic potential 
of a broad range of synthetic and naturally-occurring chemical compounds (Steele, Sharma et 
al. 1996).  Notably, the chemopreventive effects of most of these agents have been linked to 
the suppression of IKK and NF-κB through unclear mechanisms (Bharti and Aggarwal 
2002).  These chemopreventive agents include curcumin, retinoids, capsaicin, green tea 
polyphenols, caffeic acid,  phenethyl ester, and sulindac (Bharti and Aggarwal 2002).   
Additionally, many pharmaceutical companies have made advances in developing small-
molecule inhibitors and cell-permeable peptides to target IKK activity.  Due to the 
predominant role IKKβ plays in canonical NF-κB signaling, one focus has been on 
developing selective IKKβ inhibitors.  PS-1145 (Aventis Research and Technologies) 
(Cilloni, Messa et al. 2006), BMS-345541 (Yang, Amiri et al. 2006), Compound A (Bayer 
Yakuhin, Ltd.) (Duncan, Goetz et al. 2008), and BAY 11-7082 (Garcia, Alaniz et al. 2005) 
are small-molecule inhibitors of IKKβ that suppress constitutive NF-κB activity and induce 
cell death in various human cancer cell lines.  The NEMO binding domain (NBD) peptide 
was designed to interfere with IKK complex activation by blocking interaction between 
IKKγ and the C-terminal region of IKKβ (May, D'Acquisto et al. 2000).  NBD peptide was 
recently reported to effectively suppress constitutive NF-κB activity and induce cytotoxicity 
in human melanoma cell lines (Ianaro, Tersigni et al. 2009).  
     The discovery of new therapeutic strategies that target constitutive IKK/ NF-κB activity is 
dependent on understanding the complex signaling events that drives this process.  IKK and 
subsequent NF-κB activity is initiated by a diverse set of upstream signaling events.   The 
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versatility of these pathways enables molecular crosstalk between NF-κB and other signaling 
pathways.    The following sections will discuss the regulation of NF-κB by two versatile 
serine threonine kinases, transforming growth factor β-activated kinase 1 (TAK1) and 
glycogen synthase kinse-3 (GSK-3). 
 
1.5 TAK1-dependent regulation of NF-κB  
      TAK1 belongs to the evolutionarily conserved mitogen-activated protein kinase kinase 
kinase (MAP3K) family and was originally discovered to function within the transforming 
growth factor-β (TGF-β) signaling pathway (Yamaguchi, Shirakabe et al. 1995).  In addition 
to the TGF-β ligand family, this versatile serine/threonine kinase can be activated by a 
diverse set of stimuli such as interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), 
lipopolysaccharide (LPS), and latent membrane protein 1 (LMP1) (Irie, Muta et al. 2000; 
Takaesu, Surabhi et al. 2003; Wan, Sun et al. 2004).  Upon receptor activation, TAK1 can 
initiate individual downstream signaling cascades culminating in the activation of IKK and 
MAPKs (JNK and p38) (Karin, Liu et al. 1997; Takaesu, Surabhi et al. 2003).  As a result, 
NF-κB and AP-1 transcription factors are activated respectively, and promote expression of 
various cellular stress and inflammatory-response genes.   
     TAK1 activity is dependent on various phosphorylation events and interaction with 
essential signaling adapters called TAK1 binding proteins (TAB1, TAB2, and TAB3) (Fig. 
1.5).  TAB1 constitutively binds to the N-terminal activation loop of TAK1 and mediates 
autophosphorylation at threonine residues (178 and 184) and serine residue 192 following 
stimulation (Kishimoto, Matsumoto et al. 2000; Yu, Ge et al. 2008).  TAB2 and TAB3 are 
zinc-finger domain-containing adapters that bind the C-terminus of TAK1 and promote 
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recruitment to activated receptors via K63-linked polyubiquitinated signaling adapters 
(Kanayama, Seth et al. 2004; Besse, Lamothe et al. 2007).  Notably, TAB proteins have been 
demonstrated to play a crucial role in facilitating TNF-α and IL-1β-dependent activation of 
NF-κB and MAPK pathways (Kishimoto, Matsumoto et al. 2000; Besse, Lamothe et al. 
2007).  In addition to TAB proteins, prostaglandin E2 was reported to synergistically 
enhance inducible TAK1 activity via protein kinase A (PKA)-dependent phosphorylation of 
TAK1 at serine 412 (Kobayashi, Mizoguchi et al. 2005).  Due to the versatility of TAK1 
activation, other upstream signaling adapters are required to drive distinct downstream 
signaling events.  The following will describe individual TAK1-mediated pathways triggered 
by TNF or IL-1/ Toll-like receptors (Fig. 1.6). 
     TNF-dependent activation of TAK1 is initiated by the rapid recruitment of TNF receptor 
associated factors (TRAF2 and TRAF5) to TNF-α-bound receptors (Fig. 1.6A).  TRAF2 and 
TRAF5 function as E3 ubiquitin ligases and catalyze the development of polyubiquitin 
chains linked by lysine-63 (K63) of ubiquitin (Chen, Bhoj et al. 2006; Ea, Deng et al. 2006; 
Adhikari, Xu et al. 2007).  Unlike K48 polyubiquitinated proteins, K63 polyubiquitination 
does not prompt proteasomal degradation, but instead aids in scaffolding zinc finger domain-
containing adapters (Adhikari, Xu et al. 2007).  TRAF2/5 promotes the polyubiquitination of 
receptor interacting protein 1 (RIP1) (Ea, Deng et al. 2006).  The TAK1-TAB complex is 
recruited to the K63 polyubiquitinated RIP1 via the aforementioned TAB2 and TAB3 
subunits (Kanayama, Seth et al. 2004).   Once activated, the TAK1 complex can elicit 
downstream activation of p38 MAPK via MKK3/6 and JNK via MKK4/7 (Raman, Chen et 
al. 2007).   TAK1-mediated regulation of NF-κB is promoted by direct phosphorylation of 
IKKβ (serines 177 and 181) which drives downstream canonical NF-κB activity (Takaesu, 
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Surabhi et al. 2003).  Moreover, there is evidence that activation of the IKK complex by TNF 
is dependent on IKKγ (NEMO) recruitment to the K63 polyubiquitinated RIP1 (Ea, Deng et 
al. 2006).   
     Alternative to the pathway described above, TAK1 can also be activated by the sequential 
recruitment of MyD88, Tollip, and IL-1 receptor-associated kinase-1 (IRAK-1) signaling 
adaptors to the activated IL-1 or Toll-like receptors (Fig. 1.6B) (Wesche, Henzel et al. 1997; 
Burns, Clatworthy et al. 2000; Yamamoto, Takeda et al. 2004).  Subsequently, TRAF6 
oligomers are recruited to the receptor complex. TRAF6 functions as an E3 ubiquitin ligase 
and catalyzes auto-K63-polyubiquitination (Lamothe, Besse et al. 2007).  Similar to RIP1, 
TRAF6 K63 polyubiquitination is critical for the recruitment and activation of the TAK1-
TAB1-TAB2/3 complex (Besse, Lamothe et al. 2007; Lamothe, Besse et al. 2007).  IL-1R/ 
TLR-induced activation of the TAK1 complex promotes downstream NF-κB signaling 
through the phosphorylation of IKKβ, and p38-JNK MAPK signaling through the 
phosphorylation of MKK6 (Wang, Deng et al. 2001). Notably, K63 polyubiquitination plays 
a key role in IL-1R/ TLR and TNFR-dependent TAK1 signal transduction.  Thus, NF-κB-
regulated deubiquitinating enzymes (CYLD and A20) serve as critical negative feedback 
regulators of these pathways (Adhikari, Xu et al. 2007).   
    Deregulated TAK1 signal transduction has been associated with constitutive NF-κB 
activity in human cancer cell lines (Jackson-Bernitsas, Ichikawa et al. 2007; Bertrand, 
Milutinovic et al. 2008; Xie, Wang et al. 2009).  Evidence suggests that aberrant signaling 
from TNFR and Toll-like receptor 2 (TLR2) can facilitate constitutive TAK1 activation.  An 
autocrine TNF-α feedback loop was reported to mediate constitutive NF-κB activity through 
the TRADD-TRAF2-RIP-TAK1-IKK pathway in human head and neck squamous cell 
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carcinoma (HNSCC) cell lines (Jackson-Bernitsas, Ichikawa et al. 2007).  Treatment of 
HNSCC cell lines with neutralizing TNF antibody significantly downregulated TAK1 
signaling and suppressed cell proliferation (Jackson-Bernitsas, Ichikawa et al. 2007).  TNF 
autocrine feedback signaling can also drive constitutive RIP ubiquitination in the human 
breast cancer cell line, MDA-MB-231 (Bertrand, Milutinovic et al. 2008).  Additionally, 
TLR2 overexpression was recently reported in MDA-MB-231 cells to promotes constitutive 
TAK1/ NF-κB signaling and cell invasion (Xie, Wang et al. 2009).   Taken together, TAK1 
plays a key role in regulating the complex pathways leading to NF-κB activity in human 
cancers and could be considered a novel therapeutic target.  
     
1.6  GSK-3-dependent NF-κB Signal Transduction    
     Glycogen synthase kinase-3 (GSK-3) was discovered over 20 years ago as a 
serine/threonine kinase involved in the downregulation of glycogen biosynthesis through the 
phosphorylation and inactivation of glycogen synthase (Embi, Rylatt et al. 1980).  
Subsequently, GSK-3 was purified from rabbit skeletal muscle (Hemmings, Yellowlees et al. 
1981), and molecular cloning revealed that this enzyme was encoded by two independent 
genes, GSK-3α and GSK-3β (Woodgett 1990; Woodgett 1991) .  GSK-3α and GSK-3β are 
closely related mammalian isoforms that share 85% overall sequence identity and 93% 
similarity within the catalytic domain (Ali, Hoeflich et al. 2001).  A significant difference 
between GSK-3 isoforms is observed in the N-terminal region where GSK-3α possesses an 
extended glycine-rich tail (Fig. 1.7).  Although purified GSK-3 isoforms exhibit similar 
substrate properties (Woodgett 1991), evidence from GSK-3α and GSK-3β deficient mouse 
models suggest non-overlapping substrate specificities (Hoeflich, Luo et al. 2000; MacAulay, 
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Doble et al. 2007).  GSK-3α deficient mice exhibit enhanced glucose and insulin sensitivity 
(MacAulay, Doble et al. 2007), while GSK-3β deficiency is embryonic lethal at day E13.5 
due to liver degeneration (Hoeflich, Luo et al. 2000).   
     Unlike most protein kinases, GSK-3 is constitutively active in resting cells and is 
primarily regulated through inhibitory pathways (Fig. 1.8). Evidence suggests that 
constitutive GSK-3 activity is maintained by tyrosine auto-phosphorylation within the T-loop 
kinase domain at residues Y216 in GSK-3β and Y279 in GSK-3α (Fig. 1.7) (Hughes, 
Nikolakaki et al. 1993).  Although T-loop tyrosine phosphorylation has been proposed to 
mediate substrate phosphorylation, it is not strictly required for GSK-3 kinase activity 
(Dajani, Fraser et al. 2001).  In contrast, GSK-3 kinase activity can be inhibited through N-
terminal serine phosphorylation at residues S9 and S21 in GSK-3β and GSK-3α respectively 
(Fig. 1.7) (Cross, Alessi et al. 1995).  This phosphorylation results in the folding of the N-
terminus into the charged catalytic pocket of GSK-3.  As a result, a pseudosubstrate is 
created that competitively blocks binding of true GSK-3 substrates (Doble and Woodgett 
2003). 
     Various upstream signaling events have been shown to culminate to the phosphorylation 
and inactivation of GSK-3 (Fig. 1.8).  Insulin is among the most widely studied inducers of 
GSK-3 serine phosphorylation.  This pathway is driven by phosphoinositide 3-kinase-
dependent activation of Akt.  Consequently, Akt promotes the serine phosphorylation and 
inactivation of both GSK-3 isoforms (Cross, Alessi et al. 1995).  Epidermal growth factor 
(EGF) also promotes serine phosphorylation of GSK-3 through MAPK-dependent activation 
of p90RSK (also termed MAPKAP-K1) (Saito, Vandenheede et al. 1994).  Other GSK-3 
inactivating kinases include p70 ribosomal S6 kinase (p70S6K) (Armstrong, Bonavaud et al. 
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2001), cAMP-activated protein kinase (PKA) (Li, Wang et al. 2000), and protein kinase C 
(Fang, Yu et al. 2002).  Alternative to S9/21 phosphorylation, GSK-3 can also be negatively 
regulated within the Wnt/ β-catenin pathway.   
     Canonical Wnt/ β-catenin signaling is an evolutionarily conserved pathway which plays a 
key role during development by regulating cell growth, differentiation, and polarity (Frame 
and Cohen 2001).  GSK-3 is most recognized for its role in negatively regulating this 
pathway in resting cells by targeting β-catenin phosphorylation and subsequent proteasomal 
degradation (Aberle, Bauer et al. 1997).  GSK-3 functions within a β-catenin “destruction 
complex” comprised of adenomatous polyposis (APC), axin/ conductin, and β-catenin 
(Hinoi, Yamamoto et al. 2000).  Following Wnt stimulation, the activated receptor (Frizzled) 
signals to Dishevelled (Dvl) which results in the inactivation of GSK-3 through an unknown 
mechanism (Frame and Cohen 2001). Consequently, nuclear accumulation of β-catenin 
mediates the transactivation of genes regulated by the T-cell factor (TCF)/ lymphoid 
enhancer factor (LEF) family of transcription factors (Novak and Dedhar 1999).   
     GSK-3 is a multi-tasking kinase that plays an intricate role in diverse signaling pathways.  
As a consequence, GSK-3 is known to have an expanded range of substrate specificities (Fig. 
1.8). The consensus motif for GSK-3 substrates is Ser/Thr-X-X-X-Ser/Thr (X represents any 
amino acid).  GSK-3 has the unique ability to target substrates that have been previously 
phosphorylated (primed) at the C-terminal Ser/Thr residues of the consensus motif (Fiol, 
Mahrenholz et al. 1987).   For instance, the C-terminal priming serine residue of the GSK-3 
substrate, glycogen synthase, is phosphorylated by casein kinase 2 (CK2) (Frame and Cohen 
2001).  Notably, the priming of GSK-3 substrates is not required, but has been shown to 
enhance the ability of GSK-3 to phosphorylate its substrates (Thomas, Frame et al. 1999).  In 
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many cases, phosphorylation by GSK-3 results in the inactivation or proteasomal degradation 
of its substrate.  These substrates include glycogen synthase, eIF2B translational elongation 
factor (Welsh and Proud 1993), β-catenin (Yost, Torres et al. 1996), Tau microtubule-
associated protein (Hanger, Hughes et al. 1992), and cyclin D1 (Diehl, Cheng et al. 1998).  
Moreover, GSK-3 can modulate gene expression by enhancing or suppressing the activity of 
various transcription factors: c-Jun (Boyle, Smeal et al. 1991), c-Myc (Pulverer, Fisher et al. 
1994), nuclear factor of activated T-cells c (NFATc) (Beals, Sheridan et al. 1997), and cAMP 
response element binding protein (CREB) (Fiol, Williams et al. 1994).  Interestingly, there 
has been an increasing body of literature implicating the role GSK-3 plays in regulating the 
activity of NF-κB. 
     The first evidence of GSK-3-dependent regulation of NF-κB was provided by James 
Woodgett and colleagues (Hoeflich, Luo et al. 2000).  This group genetically engineered a 
mouse model in which the ATP-binding loop of GSK-β was deleted, thus rendering an 
inactive kinase.  Interestingly, embryonic lethality was observed in GSK-3β homozygous 
null mice between E13.5 and E14.5 days.  Further characterization of this phenotype showed 
these animals succumbed to multifocal hemorrhagic degeneration in the liver due to TNF-α-
dependent hepatocyte apoptosis.  Notably, this phenotype is consistent with the homozygous 
deletion of the p65 subunit of NF-κB (Beg, Sha et al. 1995) and IKKβ (Li, Van Antwerp et 
al. 1999).  To demonstrate GSK-3β-dependent NF-κB regulation, mouse embryonic 
fibroblasts from GSK-3β-deficient mice were also shown to be defective in TNF-α-induced 
NF-κB activation (Hoeflich, Luo et al. 2000).    
     The exact mechanism of how GSK-3β regulates inducible NF-κB activity remains 
controversial. Reports have implicated GSK-3β to either regulate early stages of NF-κB 
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activation (IKK complex activation and IκB degradation) or later stages (NF-κB 
transcription activity at target gene promoters).  Bharat Aggarwal and colleagues reported 
that GSK-3β null MEFs are defective in inducing IKK activity and IκBα phosphorylation/ 
degradation in response to TNF-α, IL-1β, and lipopolysaccharide (Takada, Fang et al. 2004).  
In contrast with this report, work from our lab and others have suggested that GSK-3β 
deficiency, as well as pharmacological GSK-3 inhibition diminishes cytokine-induced NF-
κB activity at the transcriptional complex level (Hoeflich, Luo et al. 2000; Schwabe and 
Brenner 2002; Steinbrecher, Wilson et al. 2005).  In fact, we demonstrated that GSK-3β 
functions to regulate the transcription of a select sub-set of NF-κB target genes (MCP-1 and 
IL-6) in response to TNF-α (Steinbrecher, Wilson et al. 2005).  Further evidence showed that 
GSK-3β can directly target the phosphorylation of p65 (amino acids 354-551), thus 
promoting NF-κB transactivation (Schwabe and Brenner 2002).  Overall, GSK-3β plays an 
essential role in crossregulating cytokine-induced NF-κB activation through either an IKK-
dependent or independent mechanism.  Due to the known pro-survival functions of NF-κB, 
studies have also focused on the potential role that GSK-3 may play during carcinogenesis.   
 
1.7  GSK-3 Inhibitors as a Targeted Therapy for Cancer  
     GSK-3 has been linked to deregulated signaling pathways leading to the pathogenesis of 
various human diseases.  Consequently, GSK-3 has emerged over the years as a therapeutic 
target for Alzheimer’s disease, bipolar disorder, dementia, and noninsulin-dependent diabetes 
mellitus (NIDDM) (Eldar-Finkelman 2002).  Moreover, there is increasing evidence linking 
aberrant GSK-3 signaling with the development of cancer.  GSK-3 is generally considered a 
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tumor suppressor due to its role in suppressing the oncogenic effects of the Wnt/ β-catenin 
pathway in colorectal cancer (Shakoori, Ougolkov et al. 2005).  However, this paradigm has 
been challenged by recent reports that suggest GSK-3 plays an oncogenic role by facilitating 
cell growth, survival, and constitutive NF-κB activity.  Advancement of these studies was 
made possible by the development of pharmacological GSK-3 inhibitors. 
     Lithium was the first tool discovered and used to inhibit GSK-3 activity (Klein and 
Melton 1996).  However, the broad kinase specificity range of lithium has prompted 
pharmaceutical companies to develop small molecule inhibitors with increased specificity for 
GSK-3 (Cohen and Goedert 2004).  SB 216763 (ATP-competitive, IC50 = 34.3 nM), SB 
415286 (ATP-competitive, IC50 = 77.5 nM), AR-A014418 (ATP-competitive, IC50 = 104 
nM), and TDZD-8 (non-ATP-competitive, IC50 = 2μM) are among the most recently 
developed GSK-3 inhibitors that have been implicated to have therapeutic potential in human 
cancers (Coghlan, Culbert et al. 2000; Martinez, Alonso et al. 2002; Bhat, Xue et al. 2003).  
Notably, these inhibitors do not provide significant selectivity between GSK-3α and GSK-
3β isoforms due to sequence identity within the kinase domain (Coghlan, Culbert et al. 2000; 
Martinez, Alonso et al. 2002; Bhat, Xue et al. 2003).   
     Studies within the past five years have implicated GSK-3 inhibitors as a potential targeted 
therapy for prostate cancer, multiple myeloma, leukemia, and pancreatic cancer.  Inhibition 
of androgen-responsive, prostate cancer cell growth was observed following GSK-3 
inhibition (SB 216763) and was associated with decreased androgen receptor function 
(Rinnab, Schutz et al. 2008).  Growth suppression and induction of apoptosis was also 
reported in multiple myeloma cell lines following treatment with TDZD-8 (Zhou, Uddin et 
al. 2008).  Moreover, SB 216763 caused the destabilization of the cyclin-dependent kinase, 
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p27Kip, and induced cell cycle arrest in MLL leukemia cell lines (Wang, Smith et al. 2008).  
Chronic lymphocytic leukemia cells were also sensitive to GSK-3 inhibition (AR-A014418) 
due to epigenetic silencing of NF-κB-responsive survival genes (Bcl-2 and XIAP) (Ougolkov, 
Bone et al. 2007).  Further evidence of GSK-3-dependent constitutive NF-κB activity was 
provided in pancreatic cancer cell lines (Ougolkov, Fernandez-Zapico et al. 2005; Ougolkov, 
Fernandez-Zapico et al. 2006).  These reports demonstrated that GSK-3 is active in 
pancreatic cancer cells, and GSK-3 inhibition (AR-A014418 and SB 216763) suppressed 
constitutive NF-κB reporter activation and target gene expression (Bcl-2, XIAP, Bcl-xL, and 
Cyclin D1) (Ougolkov, Fernandez-Zapico et al. 2005).  Furthermore, the suppression of 
constitutive NF-κB activity following GSK-3 inhibition correlated with decreased cell 
growth/ survival in both in vitro (Ougolkov, Fernandez-Zapico et al. 2005) and in vivo 
models (Ougolkov, Fernandez-Zapico et al. 2006).  Taken together, these reports establish 
GSK-3 inhibition as a potential therapeutic strategy for various human cancers.  Although the 
mechanism of action remains unclear, GSK-3 inhibitors may function partially by 
suppressing constitutive, pro-survival signaling to NF-κB.    
1.8  Conclusions 
     For more than a decade, Gemcitabine has been considered to be the standard cytotoxic 
chemotherapy to treat advanced stages of pancreatic cancer (Burris, Moore et al. 1997).  
However, the clinical benefits of Gemcitabine are limited due to the chemoresistant nature of 
this disease (Kim and Gallick 2008).  The evolution of pancreatic cancer chemotherapy is 
dependent on the development of agents that specifically target deregulated molecular 
pathways associated with disease progression (Berlin and Rothenberg 2003).  Pancreatic 
cancer is among many human malignancies that utilize constitutive signaling to the 
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transcription factor, NF-κB.  Therefore, chemotherapeutic agents that target constitutive IKK 
and subsequent NF-κB activity may be efficacious in the treatment of pancreatic cancer.  
Advancement of this therapeutic strategy requires full understanding of the complex 
molecular mechanisms that regulate constitutive IKK and NF-κB activity.  
     This chapter reviewed the critical roles GSK-3 and TAK1 play in promoting cytokine-
induced and constitutive NF-κB activity in human cancers.  Importantly, GSK-3 (Ougolkov, 
Fernandez-Zapico et al. 2005; Ougolkov, Fernandez-Zapico et al. 2006) and IKK (Li, 
Aggarwal et al. 2004) have been reported to drive constitutive NF-κB activity and cell 
growth/ survival in pancreatic cancer.  Moreover, deregulated TAK1 signaling has been 
associated with various human cancers (Jackson-Bernitsas, Ichikawa et al. 2007; Bertrand, 
Milutinovic et al. 2008; Xie, Wang et al. 2009) and may also be linked to constitutive IKK 
and NF-κB activity in pancreatic cancer.  Despite the evidence of GSK-3-dependent NF-κB 
activation in pancreatic cancer, the mechanism of regulation remains elusive.   
     The remaining chapters will characterize the requirements of GSK-3 isoforms (GSK-3α 
and GSK-3β), catalytic IKK subunits (IKKα and IKKβ), and TAK1 for maintaining 
constitutive NF-κB activity and cell growth/ survival in pancreatic cancer cells.   
Furthermore, I will investigate the potential link between these signaling components, and 
propose that constitutive NF-κB activity is driven by a unique GSK-3-TAK1-IKK signaling 
cascade.  Collectively, these studies emphasize the significance of NF-κB signaling in 
pancreatic cancer, and highlight the potential of GSK-3 and TAK1 as novel therapeutic 
targets for this disease.   
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 Figure 1.1.  Accumulation of genetic mutations during pancreatic carcinogenesis.  
Pancreatic cancer progression is characterized by three stages of pancreatic intraepithelial 
neoplasia (PanIN-1A/B, PanIN-2, and PanIN-3) followed by invasive pancreatic ductal 
adenocarcinoma (PDA).  The above “PanINgram” illustrates increasing degree of 
cytoplasmic and nuclei atypia used to classify each PanIN lesion (Maitra, Adsay et al. 2003).  
As indicated, genetic alterations in oncogenes (K-ras and Her2/ Neu) and tumor suppressors 
(p16, p53, DPC4, and BRCA2) arise during distinct stages during PanIN progression.       
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Figure 1.2.  Domain organization of NF-κB family members.  The evolutionarily 
conserved NF-κB family members indicated above exists as homo- or heterodimers.  The N-
terminal rel homology domain (RHD) mediates DNA binding and coupling with NF-κB 
family members.  NF-κB transcriptional activity is facilitated by the C-terminal 
transactivational domain (TAD).  The phosphorylation of p65 at the indicated sites has been 
shown to promote transcriptional activity.  p100 and p105 exist as precursors consisting of an 
inhibitory ankyrin repeat domain which masks nuclear localization sequence within the RHD 
of p65, RelB, and c-Rel.  Upon phosphorylation, p100 and p105 undergo proteolytic 
cleavage giving rise to mature p52 and p50 respectively. 
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Figure 1.3.  Canonical versus non-canonical NF-κB signal transduction.  (A) Canonical 
NF-κB signaling can be triggered by the indicated stimuli which converge on the activation 
of the IKK complex (IKKα, IKKβ, and IKKγ).  Upon activation, IKK phosphorylates NF-
κB-bound, IκBα at serines 32/ 36.  Consequently, IκBα undergoes rapid ubiquitination and 
subsequent proteasomal degradation.  Liberated NF-κB can undergo nuclear translocation 
and activate target gene expression.  (B)  Non-canonical NF-κB signaling can be initiated by 
the indicated stimuli which activate downstream NIK and subsequent IKKα homodimers. 
IKKα phosphorylates p100/ RelB heterodimers at serines 866/ 872.  As a result, p100 
undergoes proteolytic cleavage giving rise to an active p52/ RelB heterodimer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 25
 
 
igure 1.4.  Domain organization of IKK and IκB family members.  (A) The IKK 
ding 
c 
Bβ, 
al 
 
 
F
complex is composed of the indicated IKK family members: catalytic subunits (IKKα and 
IKKβ) and a regulatory subunit (IKKγ/ NEMO).  IKKα and IKKβ consists of a kinase 
domain, leucine zipper (LZ) domain, helix-loop-helix (HLH) domain, and a NEMO-bin
domain (NBD).  LZ and HLH facilitates IKKα/β interaction and catalytic activity (Zandi, 
Rothwarf et al. 1997).  Phosphorylation at serines 176/ 180 and 177/ 181 promotes catalyti
activity in IKKα and IKKβ respectively.  IKKα/β interaction with NEMO is dependent on 
the C-terminal NBD of IKKα/β and the coiled-coiled (CC) domain in NEMO (May, 
D'Acquisto et al. 2000).  (B) Inhibitor of κB (IκB) protein family consists of IκBα, Iκ
and IκBε.  Ankyrin repeat domains mask nuclear localization sequence of NF-κB.  PEST 
domain promotes proteasomal degradation upon phosphorylation at the indicated N-termin
serine residues. 
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Figure 1.5.  Domain organization of TAK1 and TAB proteins.  TAK1 consists of an N-
rminal kinase domain which undergoes autophosphorylation at the indicated serine/ 
AK1-
UE 
te
threonine residues upon activation.  TAK1 is also phosphorylated at serine 412 in a PKA-
dependent manner (Kobayashi, Mizoguchi et al. 2005).  TAK1 exist in complex with T
binding proteins (TAB1, TAB2, and TAB3).  TAB1 interacts with N-terminal region of 
TAK1, while TAB2/3 interacts at the C-terminal region.  TAB1 consists of an 
uncharacterized, N-terminal protein phosphatase 2C (PP2C) domain.  TAB2/3 contains C
and zinc-finger domains which facilitate interaction with polyubiquitin chains. 
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Figure 1.6.  TAK1-dependent signal transduction.  (A) TNFα-mediated TAK1 signaling 
 initiated by the recruitment of TRAF2/5 to activated TNF receptors.  TRAF2/5 promotes 
cruitment and K63 polyubiquitination of RIP1.  TAK1/ TAB complex is recruited to RIP1 
3 
.  
is
re
polyubiquitin chains and subsequently activated by phosphorylation at serine 192 and 
threonines 178, 184, and 187.  (B) IL-1β and LPS-mediated TAK1 signaling is initiated by 
recruitment of MyD88, Tollip, and IRAK1 signaling adapters to activated IL-1 or toll-like 
receptors.  TRAF6 is subsequently recruited to the receptor complex and undergoes K6
autopolyubiquitination.  TAK1/ TAB complex is recruited to K63 polyubiquitinated TRAF6
Activated TAK1 promotes downstream activation of NF-κB signaling through 
phosphorylation of IKKβ.  TAK1 also drives JNK and p38 MAPK activation through the 
phosphorylation of MKK4/7 and MKK3/6 respectively. 
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Figure 1.7.  Glycogen synthase kinase-3 isoforms. Glycogen synthase kinase-3 exist as 
o, closely related mammalian isoforms (GSK-3α and GSK-3β).  Gly-Rich indicates the N-
rminal glycine-rich region located in GSK-3α. GSK-3 activity is mediated by 
 
tw
te
autophosphorylation within the kinase domain at tyrosine residues 279 and 216 in GSK-3α
and GSK-3β respectively.  GSK-3 activity undergoes inhibitory phosphorylation at N-
terminal serine residues 21 and 9 in GSK-3α and GSK-3β respectively.   
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gulated by a variety of upstream signaling events through the phosphorylation at serines 9 
nd 21 in GSK-3β and GSK-3α respectively.  Wnts trigger phosphorylation-independent 
Figure 1.8.  GSK-3 regulatory pathways and substrate targets.  GSK-3 can be negatively 
re
a
inhibition of GSK-3 through dishevelled.  GSK-3 phosphorylates serine/ threonine residues 
in substrates that encompass the indicated substrate motif.  Select substrates require a 
priming phosphorylation event by a secondary kinase to enhance GSK-3 substrate 
phosphorylation.  The various substrates recognized by GSK-3 are indicated above.   
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CHAPTER II 
 
 
MAINTENANCE OF CONSTITUTIVE IκB KINASE ACTIVITY 
BY GLYCOGEN SYNTHASE KINASE-3 α/β IN PANCREATIC 
CANCER 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been adapted from:  Willie Wilson III and Al Baldwin.  Maintenance of 
constitutive IκB kinase activity by glycogen synthase kinase-3α/β in pancreatic cancer.  
Cancer Research 2008. 68 (19): 8156-63.
2.1 Abstract 
     Constitutive NF-κB activation is among the many deregulated signaling pathways that are 
proposed to drive pancreatic cancer cell growth and survival.  Recent reports suggest that 
glycogen synthase kinase-3β (GSK-3β) plays a key role in maintaining basal NF-κB target 
gene expression and cell survival in pancreatic cancer cell lines.  However, the mechanism 
by which GSK-3β facilitates constitutive NF-κB signaling in pancreatic cancer remains 
unclear.  In this report, we analyze the contributions of both GSK-3 isoforms (GSK-3α, 
GSK-3β) in regulating NF-κB activation and cell proliferation in pancreatic cancer cell lines 
(Panc-1 and MiaPaCa-2).  We demonstrate that GSK-3 isoforms are differentially required to 
maintain basal NF-κB DNA binding activity, transcriptional activity, and cell proliferation in 
Panc-1 and MiaPaCa-2 cells.  Our data also indicate that IKK subunits are not equally 
required to regulate pancreatic cancer-associated NF-κB activity and cell growth.  
Importantly, we provide the first evidence that GSK-3 maintains constitutive NF-κB 
signaling in pancreatic cancer by regulating IKK activity.  These data provide new insight 
into GSK-3-dependent NF-κB regulation, and further establishes GSK-3 and IKK as 
potential therapeutic targets for pancreatic cancer. 
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2.2 Introduction 
     Pancreatic cancer represents the fourth leading cause of cancer-related death in the United 
States with a five-year patient survival rate of 5% (Jemal, Siegel et al. 2007). Moreover, an 
estimated 33,370 patients were expected to die from this disease in 2007 (Jemal, Siegel et al. 
2007). The dismal mortality rate from pancreatic cancer stems from its aggressive metastatic 
nature and its ability to resist conventional chemotherapies (Sarkar, Banerjee et al. 2006).  
Therefore, expanding our knowledge of the complex molecular pathways responsible for the 
development of pancreatic cancer is critical for the discovery of new therapeutic strategies.  
Deregulated NF-κΒ and glycogen synthase kinase-3 signaling are among the many pathways 
that have been implicated in the pathogenesis of pancreatic cancer.  
     NF-κΒ represents a family of evolutionarily conserved transcription factors consisting of 
five members: c-Rel, RelA  (p65), RelB, p50 (NF-κB1/p105 precursor), and p52 (NF-
κB2/p100 precursor) (Ghosh, May et al. 1998).  The most studied NF-κΒ complex consists 
of the p65/p50 heterodimer.  In resting cells, NF-κΒ is rendered inactive within the 
cytoplasm through association with inhibitory IκΒ proteins.  Various inflammatory stimuli 
can trigger the activation of the IκΒ kinase (IKK) complex which consists of a regulatory 
subunit (IKKγ) and two catalytic subunits (IKKα and IKKβ) (Zandi, Rothwarf et al. 1997).  
Upon IKK activation, IκΒ is phosphorylated and subsequently targeted for rapid proteosomal 
degradation thus liberating NF-κΒ for nuclear translocation, enhanced DNA binding and 
transcriptional regulation (Karin and Ben-Neriah 2000).  
     Constitutive activation of NF-κΒ has been characterized in numerous human cancers and 
is associated with regulating genes that control cell survival, proliferation, metastasis, and 
angiogenesis (Aggarwal 2004).   Importantly, constitutive NF-κΒ activation has been 
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observed in 70% of human pancreatic cancers as well as in human pancreatic cancer cell 
lines and animal models (Liptay, Weber et al. 2003; Li, Aggarwal et al. 2004; Zhang and 
Rigas 2006).  Studies have also demonstrated constitutive IKK activity to play a key role in 
regulating cell survival and cell cycle progression in multiple in vitro pancreatic cancer 
models (Liptay, Weber et al. 2003; Schneider, Saur et al. 2006).  Thus, there has been 
growing interest in utilizing IKK as a chemotherapeutic target for pancreatic cancer. 
     Glycogen synthase kinase-3 (GSK-3) is a serine/theronine kinase that exists as two highly 
similar mammalian isoforms (GSK-3α and GSK-3β) (Woodgett 1990; Woodgett 1991).  
GSK-3 is recognized for its role in downregulating β-catenin, thus suppressing the 
transcriptional activity of T-cell-specific transcription factor (TCF)/lymphoid enhancer factor 
(LEF) complexes within the Wnt/β-catenin pathway (Ali, Hoeflich et al. 2001).  Numerous 
reports have subsequently demonstrated involvement of this multifunctional kinase in 
regulating a variety of transcription factors involved in cancer progression, including NF-κB 
(Fiol, Mahrenholz et al. 1987; Boyle, Smeal et al. 1991; Pulverer, Fisher et al. 1994; Beals, 
Sheridan et al. 1997; Ross, Erickson et al. 1999; Ali, Hoeflich et al. 2001).  A GSK-3β 
deficient mouse model provided the first evidence of GSK-3-dependent NF-κB regulation 
(Hoeflich, Luo et al. 2000).  These data show that the loss of GSK-3β results in defective 
NF-κB signaling in response to TNF-α.  Furthermore, we previously reported that GSK-3β 
specifies promoter-specific recruitment of p65/RelA to NF-κB-dependent genes in response 
to TNF-α (Steinbrecher, Wilson et al. 2005).  A previous report has also implicated GSK-3β 
in playing a critical role in regulating constitutive NF-κB reporter activity and target gene 
expression within in vitro pancreatic cancer models (Ougolkov, Fernandez-Zapico et al. 
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2005).  However, the mechanism by which GSK-3β drives constitutive or inducible NF-κB 
has not been characterized.   
     Despite the structural similarity between GSK-3α and GSK-3β, evidence suggests that 
these isoforms are not functionally redundant in regulating NF-κB (Hoeflich, Luo et al. 2000; 
Liang and Chuang 2006).    In this report, we characterize the individual roles that each 
GSK-3 isoform play in maintaining constitutive NF-κB activity and cell proliferation in 
pancreatic cancer cell lines (Panc-1 and MiaPaCa-2).  We show that both GSK-3 isoforms 
can function to regulate basal NF-κB DNA binding and transcriptional activity, whereas 
GSK-3α predominantly controls cell growth and survival.  Our data also demonstrate that 
IKKα and IKKβ exhibit different requirements to drive constitutive NF-κB activity in a 
pancreatic cancer cell type-dependent manner.  Additionally, we provide the first evidence 
that links GSK-3 to constitutive IKK activity in pancreatic cancer cells. 
 
2.3 Materials and Methods 
     Cell Culture and Reagents.  Panc-1 (CRL-1496) and MiaPaCa-2 (CRL-1420) pancreatic 
cancer cell lines were obtained from the American Type Culture Collection (Manassas, VA).  
Panc-1 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% fetal bovine serum and 100 units/ml penicillin/ streptomycin.  
MiaPaCa-2 cells were maintained in DMEM supplemented with 10% fetal bovine serum and 
2.5% horse serum.  Cells were cultured in DMEM supplemented with 0.5% fetal bovine 
serum for 24 hour prior to experimentation.  All cell culture reagents were obtained from 
Invitrogen (Carlsbad, CA).  The following antibodies were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA):  p65 (SC-109), p50 (SC-7178), GSK-3α/β (SC-7291), β-
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tubulin (SC-9104), and GST (SC-33613).  IKKα clone 14A231 and IKKβ clone10AG2 
antibodies were purchased from Upstate Biotechnology (Lake Placid, NY).  The following 
antibodies were obtained from Cell Signaling Technology (Beverly, MA): phospho-p65 
(serine 536), phospho-glycogen synthase (serine 641), glycogen synthase, cleaved caspase-3 
(Asp 175), and caspase-3.  TNF-α was purchased from Promega (Madison, WI).  GSK-3 
inhibitors (AR-A014418 and SB216763) were obtained from Sigma-Aldrich (St. Louis, 
MO).  The IKKβ inhibitor (Compound A) was provided by Bayer Healthcare (Wuppertal, 
Germany). 
     Small RNA interference.  The following siRNA (siGenome SMARTpool) was obtained 
from Dharmacon (Layfayette, CO) as a pool of four annealed double-stranded RNA 
oligonucleotides:  IKKα (M-003473-02), IKKβ (M-003503-03), GSK-3α (M-003009-01), 
GSK-3β (M-003010-03), and non-targeting control #3 (D001201-03).  In brief, cells were 
cultured to 70% confluency in six-well plates.  Dharmafect 1 transfection reagent 
(Layfayette, CO) was used to transfect 100nM siRNA according to manufacturer’s 
instruction.   
     Electrophoretic mobility shift assay (EMSA) and NF-κB DNA binding ELISA.  
EMSA and NF-κB super-shift analysis was performed on nuclear extracts as previously 
described (Steinbrecher, Wilson et al. 2005) using 32P-labeled oligonucleotide probe 
corresponding to an NF-κB site within the MHC class I promoter region.  Relative p65 DNA 
binding activity was quantified using the TransAM NF-κB p65 transcription factor assay kit 
(Active Motif, Carlsbad, CA) according to manufacturer’s instructions.  DNA binding 
activity was measured in triplicate at 450nm wavelength on a Versamax Microplate Reader 
(Molecular Devices Corp., Sunnyvale, CA)  
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     Western blot analysis.  Whole-cell lysates were prepared on ice using Mammalian 
Protein Extraction Reagent (M-PER) (Pierce Biotechnology, Rockford, IL) according to 
manufacturer’s instructions.  Cytoplasmic extracts were prepared as previously described 
(Mayo, Wang et al. 1997).  Protein extracts were quantified by Bradford assay (Bio-Rad 
Laboratories, Hercules, CA) and analyzed by SDS-PAGE as previously described 
(Steinbrecher, Wilson et al. 2005).   
     3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS tetrazolium) cellular proliferation assay.  Cells were seeded in 
triplicate at 3 X 103 cells per well (96-well plate) and cultured in the presence or absence of 
GSK-3 or IKKβ inhibitors at the indicated time course.   Alternatively, cells were transiently 
transfected with appropriate siRNA and cultured at the indicated time points post-
transfection.  At the end of each time point, MTS tetrazolium compound (Promega, Madison, 
WI) was added and absorbance was read at 490nm on a Versamax Microplate Reader 
(Molecular Devices Corp., Sunnyvale, CA) 
     Dual-luciferase reporter assay.  Cells were seeded in triplicate at 2 X 104 cells per well 
(24-well plate), transfected with the appropriate siRNA as described above, and cultured for 
24 hours.  After siRNA transfection, cells were co-transfected with 200ng of luciferase 
reporter construct containing tandem NF-κB binding sites from the MHC class I promoter 
region and 5ng pRL-TK Renilla luciferase construct (Promega, Madison, WI)  using Fugene6 
transfection reagent (Roche Applied Science, Indianapolis, IN).  Cells were cultured for an 
additional 24 hours, harvested in passive lysis buffer, and analyzed according to Dual-
Luciferase Assay System protocol (Promega, Madison, WI).  Relative light units were 
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measured on an Lmax Microplate Luminometer (Molecular Devices Corp., Sunnyvale, CA) 
and normalized to pRL-TK Renilla luciferase light units.   
     Real-time PCR.  Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, 
CA) according to manufacturer’s instructions.  Two micrograms of RNA was reverse 
transcribed into cDNA using Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, 
CA).  Real-time PCR was performed and analyzed as previously described (Steinbrecher, 
Wilson et al. 2005) using TaqMan Gene Expression Assay primer-probe sets (Applied 
Biosystems, Foster City, CA) for IκBα (Hs00153283_m1) and Bcl-xL (Hs00236329_m1).   
     IKK kinase assay.  Whole-cell lysate were prepared on ice for 45 minutes in the 
following lysis buffer containing 20mM Tris (pH 8.0), 500mM NaCl, 0.25% Triton-X100, 
1mM EDTA, 1mM EGTA, 1mM dithiothreitol (DTT), 1X protease inhibitor (Roche Applied 
Science, Indianapolis, IN), and 1X phosphatase inhibitor cocktail 1 (Sigma-Aldrich, St. 
Louis, MO).  IKK complexes were immunoprecipitated from 500μg protein extract using an 
IKKα antibody (Upstate Biotechnology).  An in-vitro kinase assay was performed and 
analyzed as previously described (Steinbrecher, Wilson et al. 2005).  GST-IκBα substrate 
phosphorylation was visualized by autoradiography and quantitated using Image Quant 
Version 5.2 software (Molecular Dynamics, Sunnyvale, CA).   
     Luminescent-based caspase-3/7 activity assay.   Cells were plated in triplicate at 2 x 103 
cells per well in white-walled 96-well plates (Becton Dickinson, Franklin Lakes, NJ).  Cells 
were transiently transfected with siRNA as described above.  Caspase-3/7 activity was 
measured at 48, 72, and 96 hours post-transfection using the Caspase-Glo 3/7 assay 
(Promega, Madison, WI) according to manufacturer’s instructions.  Caspase-Glo 3/7 assay 
utilizes a caspase-3/7 tetrapeptide DEVD substrate which produces a luminescent signal 
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upon cleavage. Relative light units were measured on an Lmax Microplate Luminometer 
(Molecular Devices Corp., Sunnyvale, CA). 
     Statistical analysis.  Prism software (GraphPad Software, Inc. San Diego, CA) was used 
for statistical analysis of data.  An unpaired t test was used to evaluate differences between 
group means.  P values less than 0.05 were considered to be statistically significant. 
 
2.4 Results 
     GSK-3 isoforms regulate constitutive NF-κB activity in pancreatic cancer cells.  A 
recent study emphasized the role GSK-3β plays in maintaining constitutive NF-κB reporter 
and target gene expression in pancreatic cancer cells (Ougolkov, Fernandez-Zapico et al. 
2005).    However, this report did not address the individual requirements of both GSK-3 
isoforms in regulating NF-κB.  Furthermore, the mechanism by which GSK-3 regulates NF-
κB activity requires understanding.  Here we have analyzed constitutive NF-κB DNA 
binding and transcriptional activity in two well-known in vitro pancreatic carcinoma models 
(Panc-1 and MiaPaCa-2).  As shown in Fig. 2.1A, constitutive NF-κB DNA binding activity 
is detected in Panc-1 cells through EMSA analysis of nuclear extracts. This form of NF-κB 
activity is shown to be the p65/p50 heterodimer through supershift analysis (Fig. 2.1A). 
EMSA analysis of MiaPaca-2 cells demonstrated constitutive DNA binding of p65/p50 
heterodimers as well as p50 homodimers (Fig. 2.1A).  Cells were treated with two 
structurally distinct pharmacological inhibitors of both GSK-3 isoforms (AR-A014418 and 
SB-216763) to determine a potential requirement of GSK-3 in controlling constitutive NF-
κB DNA binding activity.  Previously reported treatment duration and inhibitor 
concentrations (Ougolkov, Fernandez-Zapico et al. 2005) were used in our studies.  
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Treatment with either GSK-3 inhibitor for 24 hours at 15 and 25μM reduces p65/50 DNA 
binding in both cell lines (Fig. 2.1B).  DNA binding activity of p50 homodimers was largely 
unaffected by GSK-3 inhibition in MiaPaCa-2 cells.  To ask whether direct inhibition of 
GSK-3 isoforms would affect NF-κB constitutive DNA binding activity in pancreatic cancer 
cells, RNA interference of GSK-3α and GSK-3β was utilized.  Western blot analysis 
confirms that GSK-3 RNA interference was isoform-specific and significantly reduced GSK-
3 protein levels relative to non-targeting siRNA control (Fig. 2.1C).  Loss of either GSK-3 
isoform reduced constitutive NF-κB DNA binding in both cell lines (Fig. 2.1D).  Moreover, 
an ELISA-based DNA binding assay demonstrated a significant reduction of p65 binding 
activity following the knock-down of either GSK-3 isoform (Supplemental Fig. 2.1) 
    To determine whether GSK-3 isoforms play roles in regulating NF-κB transcriptional 
activity, we measured the effect of GSK-3 RNA interference on basal NF-κB-luciferase 
reporter activity.  Our data show that knock-down of either GSK-3 isoform resulted in a 
significant reduction of constitutive NF-κB-luciferase reporter activity in Panc-1 and 
MiaPaCa-2 cells (Fig. 2.2A).  Next, we examined whether GSK-3-dependent regulation of 
reporter activity corresponded with the expression of two NF-κB-regulated genes (IκBα and 
Bcl-xL).   Loss of GSK-3β alone and both GSK-3α/β significantly suppressed expression of 
Bcl-xL (Fig. 2.2B).  Furthermore, knock-down of either GSK-3 isoform alone or combined 
GSK-3α/β resulted in reduced expression of IκBα (Fig. 2.2B).  Serine 536 phosphorylation 
of the NF-κB subunit, p65/RelA, correlates with its transcriptional activity (Mattioli, Sebald 
et al. 2004). To determine whether the GSK-3 isoforms regulate p65 phosphorylation, RNA 
interference was used. Extracts were prepared from cells treated with control siRNA or 
siRNA for either GSK-3 isoform. Consistent with the elevated NF-κB activity in Panc-1 in 
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MiaPaCa-2 cells, we also observe constitutive serine 536 phosphorylation of p65 (Fig. 2.2C).  
RNA interference of GSK-3α or combined GSK-3α/β reduced p65 phosphorylation in Panc-
1 cells (Fig. 2.2C). Conversely, knock-down of GSK-3β had a greater effect on basal p65 
phosphorylation in MiaPaCa-2 cells (Fig. 2.2C).  Taken together, these data suggest that both 
GSK-3 isoforms play individual roles in maintaining constitutive NF-κB DNA binding and 
transcriptional activity in Panc-1 and MiaPaCa-2 cells.   
     GSK-3α promotes pancreatic cancer cell growth and survival.   Constitutive NF-κB 
activity has been reported to play mitogenic and anti-apoptotic roles in pancreatic cancer cell 
lines (Liptay, Weber et al. 2003; Li, Aggarwal et al. 2004).  Pharmacological GSK-3 
inhibition and GSK-3 RNA interference were used to determine a role for GSK-3 in 
controlling proliferation and survival of Panc-1 and MiaPaCa-2 cells. Consistent with a 
previous report (Ougolkov, Fernandez-Zapico et al. 2005), GSK-3 inhibition (AR-A014418) 
decreased growth of Panc-1 cells in a dose-dependent manner (5, 15, 30μM) over a 96 hour 
time course (Fig. 2.3A). Similar results were observed in MiaPaCa-2 cells (data not shown).  
Next, we used RNA interference to determine the individual requirements for GSK-3α and 
GSK-3β on cell viability.  We observed a significant reduction in Panc-1 cell growth 
following GSK-3α RNA interference at 96 hours post siRNA transfection when compared to 
non-targeting control and GSK-3β siRNA (Fig. 2.3B). Similar results were observed in 
MiaPaCa-2 cells (data not shown). Moreover, the knock-down of GSK-3α in Panc-1 cells 
resulted in a significant reduction in the total number of cells at 72 and 96 hours post siRNA 
transfection (Supplemental Fig. 2.2A).  Western blot analysis confirmed knock-down of 
GSK-3 isoforms at each time-point post siRNA transfection (Supplemental Fig. 2.2B).  
Importantly, we did not observe complete GSK-3 knock-down until 72 and 96 hours post 
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siRNA transfection (Supplemental Fig. 2.2B).  These data could explain why the effects of 
GSK-3α knock-down were only seen at later time-points post siRNA transfection.   
     The induction of caspase-3 cleavage was also measured to determine whether the loss of 
cell viability following the disruption of GSK-3 was due to apoptosis.  An increase in 
caspase-3 cleavage following 30μM pharmacologic GSK-3 inhibition was observed over 24 
and 48 hours in Panc-1 (Fig. 2.3C).  The efficiency of GSK-3 inhibition was indicated by the 
reduced basal phosphorylation of a GSK-3 substrate, glycogen synthase at serine 461 (Fig. 
2.3C).   Moreover, GSK-3α knock-down induced caspase-3 cleavage 48 hours post-
transfection of siRNA (Fig. 2.3D).  Similar results were observed in MiaPaCa-2 cells (data 
not shown).  A luminescent caspase-3/7 assay was used to confirm a significant increase in 
caspase activity following the knock-down of GSK-3α or combined GSK-3α/β in Panc-1 
cells (Supplemental Fig. 2.3).  Notably, pharmacologic GSK-3 inhibition was more effective 
than GSK-3 knock-down in suppressing cell growth and inducing caspase-3 cleavage.  These 
observations could indicate unknown off-target effects of pharmacologic GSK-3 inhibition 
(Fig. 2.3, see discussion).  Taken together, we show that the loss of GSK-3α is more efficient 
than GSK-3β in suppressing cell growth and survival in Panc-1 and MiaPaCa-2 cells.   
Importantly, these observations correlate with the ability of GSK-3α to regulate constitutive 
NF-κB activity. 
     Constitutive NF-κB activity in pancreatic cancer cells is IKK-dependent.  In addition 
to the studies shown above relative to GSK-3, studies have also shown IKK to be essential in 
regulating constitutive NF-κB signaling in pancreatic cancer cells (Liptay, Weber et al. 2003; 
Li, Aggarwal et al. 2004; Schneider, Saur et al. 2006).  To confirm these findings, NF-κB 
DNA binding activity was analyzed in the presence of an established small molecule IKKβ 
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inhibitor (Compound A) (Ziegelbauer, Gantner et al. 2005). Compound A treatment for 24 
hours showed dose-dependent suppression of constitutive NF-κB DNA binding activity in 
Panc-1 and MiaPaCa-2 cells (Fig. 2.4A).  We note that IKKβ inhibition is more effective in 
blocking constitutive NF-κB DNA binding activity in MiaPaCa-2 cells.  Next, RNA 
interference to IKKα and IKKβ was utilized to determine the individual requirements of IKK 
subunits for constitutive NF-κB DNA binding activity and transcriptional activation. The 
knock-down of IKK subunits was specific and significantly reduced protein levels relative to 
non-targeting siRNA control (Figure 2.4B).  We observed a decrease in p65/p50 DNA 
binding activity following the knock-down of either IKK subunit in MiaPaCa-2 cells (Fig. 
2.4C).  Interestingly, knock-down of IKKα alone or combined IKKα/β knock-down caused 
significant loss of NF-κB DNA binding activity in Panc-1 cells (Fig. 2.4C). The individual 
role that each IKK subunit plays in regulating basal NF-κB transcriptional activity was 
measured by an NF-κB reporter assay.  RNA interference against either IKK subunit caused 
substantial suppression of reporter activity in both Panc-1 and MiaPaCa-2 cells (Fig. 2.4D).  
However, the suppressive effect of IKKα and combined IKKα/β knock-down were stronger 
than IKKβ knock-down alone (Fig. 2.4D).  Thus, our data suggests that both IKK subunits 
play a role in regulating constitutive NF-κB activity in pancreatic cancer cells, but IKKα 
may play a more significant role in Panc-1 cells. 
     IKK regulates pancreatic cancer cell growth and survival.  To determine the 
functional significance of NF-κB regulation by IKK in pancreatic cancer cells, growth and 
survival was measured following IKKβ inhibition (Compound A) or IKK RNA interference.  
We showed that a higher concentration of Compound A (5μM) was required to significantly 
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reduce Panc-1 cell growth (Fig. 2.5A). However, MiaPaCa-2 cells were more sensitive to 
increasing concentration of Compound A, as shown by significant loss of cell growth after 48 
hour treatment at 1, 3, and 5μM (Fig. 2.5A).    These results are consistent with our previous 
observations of Compound A being more effective in suppressing constitutive NF-κB DNA 
binding in MiaPaCa-2 cells (Fig. 2.4A). Cell growth was also measured in cells at 48, 72, and 
96 hours post-transfection of IKKα and IKKβ siRNA.  Furthermore, we used p65/RelA RNA 
interference to test the dependency of NF-κB for cell growth.  In Panc-1 cells, loss of either 
IKK subunit or p65/RelA significantly reduced cell growth 48 hours post siRNA transfection 
(Fig. 2.5B).  However, knock-down of IKKα and p65/RelA was more effective in 
suppressing cell growth at the 72 and 96 hour time-points (Fig. 2.5B).  In MiaPaCa-2 cells, 
knockdown of IKKα, IKKβ, and p65/RelA each resulted in a significant reduction in cell 
growth 96 hours post siRNA transfection (Fig. 2.5B).  We note that MiaPaCa-2 cell growth is 
more sensitive to the loss of both IKK subunits, while Panc-1 cell growth is more dependent 
on IKKα.  While siRNA effects are not complete in their ability to knockdown individual 
proteins, these experiments demonstrate that the IKK subunits and p65/RelA are involved in 
growth/ survival of pancreatic cancer cells.   
     The induction of caspase-3 cleavage was also measured to determine whether the 
reduction of cell growth following the disruption of IKK was due to apoptosis.  We observe a 
dose-dependent increase in caspase-3 cleavage upon 24 hour treatment with Compound A in 
Panc-1 cells (Fig. 2.5C).  Similar results were obtained with MiaPaCa-2 cells (data not 
shown).  Additionally, maximal caspase-3 cleavage was induced in Panc-1 cells following 
knock-down of both IKKα and IKKβ subunits (Fig. 2.5D).  Furthermore, we observe a 
significant increase in caspase-3/7 activity following RNA interference against either IKKα 
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or IKKβ (Supplemental Fig. 2.4).  Overall, our data suggest that differential NF-κB 
regulation by IKK subunits correlates with cell growth and survival in Panc-1 and MiaPaCa-
2 cells. 
     GSK-3 is required for constitutive IKK activity.   The mechanism by which GSK-3 
regulates constitutive NF-κB signaling in pancreatic cancer is poorly understood.  Our data 
thus far has shown that loss of GSK-3 isoforms and IKK subunits suppresses constitutive 
NF-κB activity, cell growth and survival in Panc-1 and MiaPaCa-2 cells.  To determine 
whether GSK-3 regulates constitutive IKK activity in pancreatic cancer cells, the effects of 
pharmacological GSK-3 inhibition on IKK-dependent IκBα phosphorylation was measured 
via an in vitro IKK kinase assay.  Panc-1 cells were treated for 24 hours with GSK-3 
inhibitor (AR-A014418) at 25 and 50μM.  Endogenous IKK complexes were 
immunoprecipitated using an IKKα-specific antibody.  Immunoprecipitates were incubated 
with GST-IκBα and an in vitro kinase reaction was performed. GSK-3 inhibition reduced 
phosphorylation of GST-IκBα in a dose-dependent manner (Fig. 2.6A).  Moreover, the basal 
phosphorylation status of IκBα at serine 32/36 was measured in Panc-1 cells following the 
knock-down of both GSK-3 isoforms.  Consistent with our in vitro kinase assay data, the loss 
of GSK-3 also resulted in a reduction of endogenous IκBα phosphorylation (Fig. 2.6B), and 
is consistent with an inhibition of IKK activity. Notably, these data provide the first evidence 
that GSK-3 regulates cancer cell-associated NF-κB by maintaining IKK activity (Fig. 2.7).    
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2.5 Discussion
     GSK-3β has been previously reported to play an essential role in maintaining constitutive 
NF-κB reporter activity and expression of NF-κB target genes in pancreatic cancer cells 
(Ougolkov, Fernandez-Zapico et al. 2005).  In this study, we show that both GSK-3 isoforms 
function to regulate constitutive NF-κB activity in Panc-1 and MiaPaCa-2 cells.  Although 
both GSK-3 isoforms contribute to regulating NF-κB activity, GSK-3α was shown to be 
primarily required for cell growth (Fig. 2.3B and Supplemental Fig. 2.2A).  Moreover, the 
suppression in cell growth following the loss GSK-3α may be due to increased apoptotic 
signaling, as shown by an induction of caspase-3 activity (Fig. 2.3D and Supplemental Fig. 
2.3).   We note that pharmacological inhibition of GSK-3 was more effective than GSK-3α 
knock-down in suppressing Panc-1 cell growth (Fig. 2.3A and 2.3B).  Although the GSK-3 
inhibitor (AR-A014418) was not shown to affect a panel of closely related protein kinases 
(Bhat, Xue et al. 2003), unknown off-target effects cannot be ruled out when interpreting 
growth inhibition in pancreatic cancer cells.  Importantly, we show that complete knock-
down of GSK-3 and significant growth suppression was not observed until later time-points 
post siRNA transfection (Supplemental Fig. 2.2).  These data may also explain why GSK-3α 
siRNA was less effective in suppressing cell growth relative to GSK-3 pharmacologic 
inhibition.  Overall, our data suggest that GSK-3 isoforms are not functionally redundant in 
regulating NF-κB activity and cell growth in pancreatic cancer cells.   
     IκB kinases play a central role in regulating NF-κB signal transduction.  Therefore, efforts 
have been made in utilizing IKK as a therapeutic target to block constitutive NF-κB activity.  
In this report, we use an IKKβ-specific small molecule inhibitor (Compound A) that has been 
shown to be effective in blocking constitutive (Duncan, Goetz et al. 2008) and inducible 
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(Ziegelbauer, Gantner et al. 2005) NF-κB activity in various cell lines.  Our data shows that 
Compound A is also efficient in inhibiting constitutive NF-κB activity (Fig. 2.4) and cell 
proliferation (Fig. 2.5) in pancreatic cancer cells.  In addition to IKKβ inhibition, we show 
that IKKα is the predominant regulator of constitutive NF-κB activity and cell growth in 
Panc-1 (Fig. 2.4, 2.5).  Notably, higher concentrations of the IKKβ inhibitor (Compound A) 
were required to diminish Panc-1 cell growth.  These data raises the possibility that 
Compound A may target IKKα at higher doses.  Indeed, Comound A was shown to inhibit 
recombinant IKKα activity at higher concentrations (Ki for ATP: 135nM) (Ziegelbauer, 
Gantner et al. 2005).  Overall, we show that the individual requirements for IKKα and IKKβ 
for driving NF-κB activity vary between Panc-1 and MiaPaCa-2 cells.  These data 
underscore the heterogeneity between pancreatic carcinoma cell lines and prompts the need 
to understand the variety of oncogenic mutations that potentiates NF-κB activity. Moreover, 
our results emphasize the need for IKKα-specific small molecule inhibitors to target 
constitutive NF-κB activity in select pancreatic carcinoma cell types. 
     The mechanism by which GSK-3 regulates constitutive NF-κB activity in pancreatic 
cancer is not fully understood.  Our data suggests that GSK-3 and IKK may function together 
to regulate constitutive NF-κB activity.  Previous reports have speculated on whether IKK is 
required for GSK-3-dependent NF-κB activity.  Analysis from our group and others provide 
evidence that GSK-3β functions independent of the IKK complex during TNF-α-induced 
NF-κB signaling (Hoeflich, Luo et al. 2000; Schwabe and Brenner 2002; Steinbrecher, 
Wilson et al. 2005).  Moreover, GSK-3 was also suggested to function independent of IKKβ 
in pancreatic cancer cell lines(Ougolkov, Fernandez-Zapico et al. 2005).   In this regard, our 
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current data demonstrates GSK-3-dependent regulation of constitutive IKK activity in certain 
pancreatic cancer cell lines.  We show that inhibition (AR-A014418) or knock-down of both 
GSK-3 isoforms suppressed constitutive IKK activity in Panc-1 cells (Fig. 2.6).  Notably, this 
abrogation in constitutive IKK activity correlated with reduced NF-κB activity, cell growth, 
and survival. Thus, we provide the first evidence that links GSK-3 and IKK in constitutive 
NF-κB signaling in pancreatic cancer cells (Fig. 2.7).  Further studies are needed to 
determine whether GSK-3 directly or indirectly regulates IKK activity.   
     Pancreatic cancer is a highly aggressive, metastatic disease known for its dismal mortality 
rate.  Despite current chemotherapeutic efforts to improve clinical prognosis, pancreatic 
cancer still remains to be among the most drug-resistant tumors.  Consequently, there is 
growing interest on specifically targeting deregulated signaling pathways that drive the 
molecular pathogenesis of pancreatic cancer.  We emphasize in this report the critical roles 
both GSK-3 and IKK play in maintaining constitutive NF-κB signaling.  Collectively, our 
data provide new insight into GSK-3-dependent NF-κB regulation, and further establishes 
GSK-3 and IKK as potential therapeutic targets for pancreatic cancer.  
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Figure 2.1.  GSK-3 is required for constitutive NF-κB DNA binding.  EMSA was 
performed on Panc-1 and MiaPaCa-2 nuclear extracts using 32P-labeled NF-κB-specific 
probe. (A) Super-shift analysis was performed using antibodies against p65 and p50. Arrows 
indicate p65/50 and p50/p50 NF-κB complexes.  Non-specific binding is specified by NS. 
(B) Cells were treated with vehicle control (DMSO) or GSK-3 inhibitors (AR-A014418 and 
SB216763) at 15 and 25μM for 24 hours. (C) Panc-1 cells were transiently transfected with 
100nM siRNA targeted against GSK-3α, GSK-3β, combined GSK-3α/β, and non-targeting 
control (siCTRL) for 48 hours.  Cytoplasmic extracts were harvested and separated by SDS-
PAGE. Immunoblots were performed using the specified antibodies. (D) Nuclear extracts 
were harvested from Panc-1 and MiaPaCa-2 cells transfected with siRNA as described above 
and EMSA was performed. 
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Figure 2.2. GSK-3 regulates NF-κB transcriptional activity.  (A) Panc-1 and MiaPaCa-2 
cells were transiently transfected with 100nM siRNA targeted against GSK-3α, GSK-3β, 
combined GSK-3α/β, and non-targeting control (siCTRL) for 24 hours.  Cells were 
subsequently transfected with 3X-NF-κB and renilla luciferase reporter constructs for 24 
hours.  Luciferase activity was measured in triplicate and indicated as % activity relative to 
siCTRL.  Reporter activity from cells transfected with GSK-3 siRNA were all found to be 
significantly different relative to siCTRL (P < 0.05).  (B) Panc-1 cells were transfected with 
siRNA as described above for 48 hours.  RNA was harvested and expression of IκBα and 
Bcl-xL was analyzed by real-time PCR in triplicate.  Astericks indicates statistical 
significance relative to siCTRL (P < 0.05). (C) Panc-1 and MiaPaCa-2 were transiently 
transfected with siRNA as described above for 48 hours.  Whole cell extracts were harvested 
and separated by SDS-PAGE.  Immunoblots were performed using the specified antibodies.   
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Figure 2.3.  Blockade of GSK-3 suppresses cell proliferation.  (A) Panc-1 cells were 
treated with DMSO or 5, 15, and 30μM of the GSK-3 inhibitor (AR-A014418) for 48, 72, 
and 96 hours.  Cell growth was measured in triplicate at each time-point using a colormetric 
MTS tetrazolium assay.  (B) Panc-1 cells were transiently transfected with siRNA targeted 
against GSK-3α, GSK-3β and siCTRL.  Cell growth was measured as described above at 48, 
72, and 96 hours post-transfection.  Data was normalized to the initial cell density prior to 
GSK-3 inhibitor treatment or siRNA transfection respectively. Astericks indicates statistical 
significance relative to siCTRL (P < 0.05).  (C)  Panc-1 cells were treated with DMSO or 
30μM of GSK-3 inhibitors (AR-A014418 and SB216764) for 24 and 48 hours.  Whole-cell 
extracts were harvested and separated by SDS-PAGE.  (D) Panc-1 cells were transiently 
transfected with 100nM siRNA targeted against GSK-3α, GSK-3β, combined GSK-3α/β, 
and siCTRL for 48 hours.  Whole-cell extracts were harvested and separated by SDS-PAGE.  
Immunoblots were performed using the specified antibodies. 
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Figure 2.4. IKK is required for constitutive NF-κB activation.  (A) Panc-1 and MiaPaCa-
2 cells were treated with DMSO or 0.5, 1, 3, and 5μM of IKKβ inhibitor (Compound A) for 
24 hours.  Nuclear extracts were harvested and EMSA was performed using 32P-labeled NF-
κB-specific probe.  Arrows indicate NF-κB complexes as determined by supershift analysis 
in Fig.1A.  Non-specific binding is indicated with NS. (B) Panc-1 cells were transiently 
transfected with 100nM siRNA targeted against IKKα, IKKβ, combined IKKα/β, and 
siCTRL for 48 hours. Cytoplasmic extracts were harvested from cells transfected with 
siRNA as described above.  Extracts were separated by SDS-PAGE and immunoblots were 
performed using the specified antibodies.  (C) EMSA was performed on nuclear extracts 
harvested from cells transfected with siRNA as described above. (D) Panc-1 and MiaPaCa-2 
cells were transfected with siRNA as described above for 24 hours.  Cells were subsequently 
transfected with 3X-NF-κB and renilla luciferase reporter constructs for 24 hours.  
Luciferase activity was measured in triplicate and indicated as % activity relative to siCTRL.  
Reporter activity from cells transfected with IKK siRNA were all found to be significantly 
different relative to siCTRL.   
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Figure 2.5.  Blockade of IKK suppresses cell proliferation.  (A) Panc-1 and MiaPaCa-2 
cells were treated with DMSO or 1, 3, and 5μM of IKKβ inhibitor (Compound A) for 48, 72, 
and 96 hours. Cell growth was measured in triplicate at each time-point using a colormetric 
MTS tetrazolium assay.  (B) Panc-1 and MiaPaCa-2 cells were transiently transfected with 
100nM siRNA targeted against IKKα, IKKβ, p65, and siCTRL.  Cell growth was measured 
as described above at 48, 72, and 96 hours post-transfection. Data was normalized to the 
initial cell density prior to Compound A treatment or siRNA transfection respectively. 
Asterisks indicate statistical significance relative to DMSO or siCTRL (P < 0.05). (C) Panc-1 
cells were treated with Compound A as described above for 24 hours. Whole-cell extracts 
were harvested and separated by SDS-PAGE.  (D) Panc-1 cells were transiently transfected 
with 100nM siRNA targeted against IKKα, IKKβ, combined IKKα/β, and siCTRL.  Whole-
cell extracts were harvested, separated by SDS-PAGE, and immunoblotted using the 
specified antibodies. 
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Figure 2.6.  GSK-3 inhibition suppresses constitutive IKK kinase activity.  (A) Panc-1 
cells were treated with DMSO or GSK-3 inhibitor (AR-A014418) at 25 and 50μM for 24 
hours. As control, cells were treated with 10ng/ml TNF-α for 15min. Whole cells extracts 
were harvested.  IKKα antibody was used to immunoprecipitate IKK complex.  Kinase 
activity within immunocomplexes were assayed following incubation with wild-type GST-
IκBα substrate in the presence of γ[32P]-ATP.  Autoradiography was quantified and indicated 
as fold induction relative to DMSO.  Immunoblots were performed against IKKα and GST to 
confirm equal loading.  (B) Panc-1 cells were treated with 10ng/ml TNF-α for 15 minutes or 
transiently transfected with 100nM siRNA targeted against GSK-3α/β and siCTRL for 48 
hours.  Whole-cell extracts were harvested, separated by SDS-PAGE, and immunoblotted 
using the specified antibodies. 
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Figure 2.7.  Model for GSK-3-dependent regulation of constitutive NF-κB activity in 
pancreatic cancer cells.   GSK-3 regulates constitutive IKK phosphorylation (serine 176/ 
180) and activity through an undefined mechanism (dashed arrow).  IKK facilitates the 
phosphorylation (serine 32/ 36) and rapid proteosomal degradation of IκBα.  Consequently, 
NF-κB (p65/ p50 heterodimer) is activated and regulates gene expression required for cell 
growth and survival of pancreatic cancer cells.  GSK-3 inhibition (AR-A014418) and GSK-3 
knock-down suppresses constitutive IKK activity.  IKKβ inhibition (Compound A) and 
IKKα/β siRNA down-regulates pro-survival NF-κB signaling. 
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Supplemental Figure 2.1.  GSK-3 regulates basal p65 DNA binding activity.  Panc-1 and 
MiaPaCa-2 cells were transiently transfected with 100nM siRNA targeted against GSK-3α, 
GSK-3β, combined GSK-3α/β, and non-targeting control (siCTRL) for 48 hours.  Nuclear 
extracts were harvested and p65 DNA binding activity was measured using an NF-κB DNA 
binding ELISA.  Samples were measured at 450nm in triplicate and indicated as % siCTRL.  
Astericks indicates statistical significance relative to siCTRL (P < 0.05).   
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Supplemental Figure 2.2.  Loss of GSK-3α attenuates cellular proliferation.  (A) Panc-1 
cells were plated in triplicate at 1 x 105 cells per well (six-well plate).  Cells were transfected 
with 100nM siRNA targeted against GSK-3α, GSK-3β and non-targeting (siCTRL).  Cells 
were harvested and total cell counts were performed at 48, 72, and 96 hours post-
transfection.  Astericks indicates statistical significance relative to siCTRL (P < 0.05). (B)  
Whole-cell extracts from each time point described above were harvested and separated by 
SDS-PAGE.  Immunoblots were performed using antibodies against GSK-3α/β to confirm 
sufficient knock-down of GSK-3 isoforms at each time point post siRNA transfection.   
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Supplemental Figure 2.3.  Loss of GSK-3α induces caspase-3/7 activity.  Panc-1 cells 
were transfected with 100nM siRNA targeted against GSK-3α, GSK-3β, combined GSK-
3α/β, and non-targeting (siCTRL).  Relative caspase-3/7 activity was measured in triplicate 
at 72 hours post siRNA transfection using a luminescent caspase-3/7 assay.  Astericks 
indicates statistical significance relative to siCTRL (P < 0.05). 
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Supplemental Figure 2.4.  Knock-down of IKK induces caspase-3/7 activity.  Panc-1 
cells were transfected with 100nM siRNA targeted against IKKα, IKKβ, combined IKKα/β, 
and non-targeting (siCTRL).  Relative caspase-3/7 activity was measured in triplicate at 72 
hours post siRNA transfection using a luminescent caspase-3/7 assay.  Astericks indicates 
statistical significance relative to siCTRL (P < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 73
References 
Aggarwal, B. B. (2004). "Nuclear factor-kappaB: the enemy within." Cancer Cell 6(3): 203-
8. 
Ali, A., K. P. Hoeflich and J. R. Woodgett (2001). "Glycogen synthase kinase-3: properties, 
functions, and regulation." Chem Rev 101(8): 2527-40. 
Beals, C. R., C. M. Sheridan, C. W. Turck, P. Gardner and G. R. Crabtree (1997). "Nuclear 
export of NF-ATc enhanced by glycogen synthase kinase-3." Science 275(5308): 
1930-4. 
Bhat, R., Y. Xue, S. Berg, S. Hellberg, M. Ormo, Y. Nilsson, A. C. Radesater, E. Jerning, P. 
O. Markgren, T. Borgegard, M. Nylof, A. Gimenez-Cassina, F. Hernandez, J. J. 
Lucas, J. Diaz-Nido and J. Avila (2003). "Structural insights and biological effects of 
glycogen synthase kinase 3-specific inhibitor AR-A014418." J Biol Chem 278(46): 
45937-45. 
Boyle, W. J., T. Smeal, L. H. Defize, P. Angel, J. R. Woodgett, M. Karin and T. Hunter 
(1991). "Activation of protein kinase C decreases phosphorylation of c-Jun at sites 
that negatively regulate its DNA-binding activity." Cell 64(3): 573-84. 
Duncan, E. A., C. A. Goetz, S. J. Stein, K. J. Mayo, B. J. Skaggs, K. Ziegelbauer, C. L. 
Sawyers and A. S. Baldwin (2008). "IkappaB kinase beta inhibition induces cell death 
in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells." Mol Cancer 
Ther 7(2): 391-7. 
Fiol, C. J., A. M. Mahrenholz, Y. Wang, R. W. Roeske and P. J. Roach (1987). "Formation 
of protein kinase recognition sites by covalent modification of the substrate. 
Molecular mechanism for the synergistic action of casein kinase II and glycogen 
synthase kinase 3." J Biol Chem 262(29): 14042-8. 
Ghosh, S., M. J. May and E. B. Kopp (1998). "NF-kappa B and Rel proteins: evolutionarily 
conserved mediators of immune responses." Annu Rev Immunol 16: 225-60. 
Hoeflich, K. P., J. Luo, E. A. Rubie, M. S. Tsao, O. Jin and J. R. Woodgett (2000). 
"Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB 
activation." Nature 406(6791): 86-90. 
 74
Jemal, A., R. Siegel, E. Ward, T. Murray, J. Xu and M. J. Thun (2007). "Cancer statistics, 
2007." CA Cancer J Clin 57(1): 43-66. 
Karin, M. and Y. Ben-Neriah (2000). "Phosphorylation meets ubiquitination: the control of 
NF-[kappa]B activity." Annu Rev Immunol 18: 621-63. 
Li, L., B. B. Aggarwal, S. Shishodia, J. Abbruzzese and R. Kurzrock (2004). "Nuclear factor-
kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and 
their down-regulation by curcumin (diferuloylmethane) is associated with the 
suppression of proliferation and the induction of apoptosis." Cancer 101(10): 2351-
62. 
Liang, M. H. and D. M. Chuang (2006). "Differential roles of glycogen synthase kinase-3 
isoforms in the regulation of transcriptional activation." J Biol Chem 281(41): 30479-
84. 
Liptay, S., C. K. Weber, L. Ludwig, M. Wagner, G. Adler and R. M. Schmid (2003). 
"Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in 
pancreatic cancer." Int J Cancer 105(6): 735-46. 
Mattioli, I., A. Sebald, C. Bucher, R. P. Charles, H. Nakano, T. Doi, M. Kracht and M. L. 
Schmitz (2004). "Transient and selective NF-kappa B p65 serine 536 phosphorylation 
induced by T cell costimulation is mediated by I kappa B kinase beta and controls the 
kinetics of p65 nuclear import." J Immunol 172(10): 6336-44. 
Mayo, M. W., C. Y. Wang, P. C. Cogswell, K. S. Rogers-Graham, S. W. Lowe, C. J. Der and 
A. S. Baldwin, Jr. (1997). "Requirement of NF-kappaB activation to suppress p53-
independent apoptosis induced by oncogenic Ras." Science 278(5344): 1812-5. 
Ougolkov, A. V., M. E. Fernandez-Zapico, D. N. Savoy, R. A. Urrutia and D. D. Billadeau 
(2005). "Glycogen synthase kinase-3beta participates in nuclear factor kappaB-
mediated gene transcription and cell survival in pancreatic cancer cells." Cancer Res 
65(6): 2076-81. 
Pulverer, B. J., C. Fisher, K. Vousden, T. Littlewood, G. Evan and J. R. Woodgett (1994). 
"Site-specific modulation of c-Myc cotransformation by residues phosphorylated in 
vivo." Oncogene 9(1): 59-70. 
Ross, S. E., R. L. Erickson, N. Hemati and O. A. MacDougald (1999). "Glycogen synthase 
kinase 3 is an insulin-regulated C/EBPalpha kinase." Mol Cell Biol 19(12): 8433-41. 
 75
Sarkar, F. H., S. Banerjee and Y. Li (2006). "Pancreatic cancer: Pathogenesis, prevention and 
treatment." Toxicol Appl Pharmacol. 
Schneider, G., D. Saur, J. T. Siveke, R. Fritsch, F. R. Greten and R. M. Schmid (2006). 
"IKKalpha controls p52/RelB at the skp2 gene promoter to regulate G1- to S-phase 
progression." Embo J 25(16): 3801-12. 
Schwabe, R. F. and D. A. Brenner (2002). "Role of glycogen synthase kinase-3 in TNF-
alpha-induced NF-kappaB activation and apoptosis in hepatocytes." Am J Physiol 
Gastrointest Liver Physiol 283(1): G204-11. 
Steinbrecher, K. A., W. Wilson, 3rd, P. C. Cogswell and A. S. Baldwin (2005). "Glycogen 
synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent 
transcription." Mol Cell Biol 25(19): 8444-55. 
Woodgett, J. R. (1990). "Molecular cloning and expression of glycogen synthase kinase-
3/factor A." Embo J 9(8): 2431-8. 
Woodgett, J. R. (1991). "cDNA cloning and properties of glycogen synthase kinase-3." 
Methods Enzymol 200: 564-77. 
Zandi, E., D. M. Rothwarf, M. Delhase, M. Hayakawa and M. Karin (1997). "The IkappaB 
kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, 
necessary for IkappaB phosphorylation and NF-kappaB activation." Cell 91(2): 243-
52. 
Zhang, Z. and B. Rigas (2006). "NF-kappaB, inflammation and pancreatic carcinogenesis: 
NF-kappaB as a chemoprevention target (review)." Int J Oncol 29(1): 185-92. 
Ziegelbauer, K., F. Gantner, N. W. Lukacs, A. Berlin, K. Fuchikami, T. Niki, K. Sakai, H. 
Inbe, K. Takeshita, M. Ishimori, H. Komura, T. Murata, T. Lowinger and K. B. 
Bacon (2005). "A selective novel low-molecular-weight inhibitor of IkappaB kinase-
beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-
inflammatory activity." Br J Pharmacol 145(2): 178-92. 
 
 
 76
CHAPTER III 
 
GLYCOGEN SYNTHASE KINASE-3 DRIVES CONSTITUTIVE 
TAK1-IKK SIGNALING IN PANCREATIC CANCER CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of this chapter have been adapted from:  Willie Wilson III and Al Baldwin.  
Glycogen synthase kinase-3 drives constitutive TAK1-IKK signaling in pancreatic cancer 
cells.  2009. Manuscript in progress.
3.1 Abstract  
     Recent evidence has implicated glycogen synthase kinae-3 (GSK-3) in the regulation of 
constitutive NF-κB activity in pancreatic cancer.  However, the mechanism by which GSK-3 
drives constitutive NF-κB activity remains elusive.  We previously, reported that GSK-3 
signals through IKK to facilitate downstream NF-κB signaling in pancreatic cancer cells.  
Here, we expand this model and examine the functional link between GSK-3 and IKK.  TGF-
β activated kinase 1 (TAK1) is a known regulator of IKK activity and has shown to be active 
in human cancers.  In this report, we provide initial evidence that TAK1 is constitutively 
active in pancreatic cancer cells and plays a role in pro-survival NF-κB signaling.  We show 
that the phosphorylation of TAK1 at serine 412 can be suppressed following GSK-3 
inhibition (AR-A014418) and GSK-3 knock-down in Panc-1 and MiaPaCa-2 cells.  
Importantly, we observe a correlation between TAK phosphorylation at serine 412 and IKK 
activity.  Overall, we propose that constitutive NF-κB activity in pancreatic cancer is driven 
by a novel GSK-3-TAK1-IKK signaling cascade.  However, link between GSK-3 and TAK1 
remains to be discovered.  These data provide new insight into our understanding of 
constitutive NF-κB regulation in pancreatic cancer and presents TAK1 as a potential new 
therapeutic target for this disease.   
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3.2 Introduction 
 
     Pancreatic cancer is the most common malignancy of the pancreas and is ranked the 4th 
leading cause of cancer-related deaths in the United States (Jemal, Siegel et al. 2008).  
Despite current therapeutic strategies, only 5% of patients diagnosed with this disease are 
expected to survive past 5 years (Jemal, Siegel et al. 2008).  Advancements in pancreatic 
cancer chemotherapy have evolved into specifically targeting the many deregulated signaling 
pathways associated with disease progression (Berlin and Rothenberg 2003).  Current 
research efforts have focused on understanding the complex mechanisms underlying 
constitutive activity of the transcription factor, NF-κB, in pancreatic cancer (Sarkar, Banerjee 
et al. 2006).   
     NF-κB represents a family of evolutionarily conserved, dimeric transcription factors 
consisting of RelA (p65), c-Rel, RelB, p50 (p105 precursor), or p52 (p100 precursor) 
subunits (Ghosh, May et al. 1998).  The most abundant NF-κB complex consists of the 
p65/p50 heterodimer (Ghosh, May et al. 1998).  NF-κB is sequestered in the cytoplasm of 
resting cells by interacting with inhibitory, IκB proteins.  Classical NF-κB signal 
transduction is dependent on the activation of an IκB kinase (IKK) complex which consists 
of catalytic subunits (IKKα and IKKβ), and a regulatory subunit (IKKγ) (Zandi, Rothwarf et 
al. 1997).  Following IKK complex activation, IκB undergoes phosphorylation and 
subsequent proteasomal degradation (Karin and Ben-Neriah 2000).  Consequently, NF-κB 
can translocate to the nucleus and facilitate transcription of various target genes that regulate 
inflammation, proliferation, and apoptosis (Ghosh and Karin 2002).   
     Constitutive NF-κB activity has been linked to the progression of multiple human cancers 
and is the focus for targeted chemotherapies (Bharti and Aggarwal 2002; Aggarwal 2004).  
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NF-κB is constitutively active in 70% of pancreatic cancers and is known to facilitate cell 
proliferation and survival in vitro (Zhang and Rigas 2006).  Work from our lab and others 
has demonstrated that constitutive NF-κB activity is dependent on IKK in pancreatic cancer 
cell lines (Liptay, Weber et al. 2003; Li, Aggarwal et al. 2004; Wilson and Baldwin 2008).  
The signaling events that drive constitutive IKK activity are not well understood.  However, 
we recently showed that glycogen synthase kinase-3 (GSK-3) may play a key regulatory role 
in this pathway (Wilson and Baldwin 2008). 
     GSK-3 is a multifunctional serine/ threonine kinase that exists as two closely related 
isoforms (GSK-3α and GSK-3β) (Woodgett 1990; Woodgett 1991).  Numerous reports have 
characterized GSK-3 as a key enzyme involved in diverse biological processes such as cell 
cycle progression, differentiation, and apoptosis (Doble and Woodgett 2003).  Moreover, 
GSK-3 has recently been implicated as playing an oncogenic role in various human 
malignancies including pancreatic cancer (Doble and Woodgett 2003; Ougolkov, Fernandez-
Zapico et al. 2005; Ougolkov, Bone et al. 2007; Rinnab, Schutz et al. 2008; Wang, Smith et 
al. 2008; Zhou, Uddin et al. 2008).  In fact, evidence suggests that GSK-3 regulates cell 
growth and survival in pancreatic cancer cell lines by driving constitutive NF-κB activity 
(Ougolkov, Fernandez-Zapico et al. 2005; Ougolkov, Fernandez-Zapico et al. 2006; Wilson 
and Baldwin 2008).  Although the mechanism remains elusive, we recently proposed GSK-3 
potentiates constitutive IKK and subsequent NF-κB activity in pancreatic cancer cells 
through an unknown mechanism.    
     Transforming growth factor beta activated kinase 1 (TAK1) is a mitogen activated protein 
kinase kinase kinase (MAP3K) that can initiate downstream NF-κB and MAPK signaling 
cascades in response to cytokines (Ninomiya-Tsuji, Kishimoto et al. 1999).  TAK1 activity is 
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dependent on its association with TAK1-binding proteins (TAB1, TAB2, TAB3) which 
facilitate auto-phosphorylation (Thr184, Thr178, Ser192) within the kinase activation loop 
(Kishimoto, Matsumoto et al. 2000; Yu, Ge et al. 2008) and recruitment to activated receptor 
complexes (Kanayama, Seth et al. 2004; Besse, Lamothe et al. 2007).  Moreover, 
prostaglandin E2 was reported to enhance cytokine-induced TAK1 activity due to cyclic 
AMP-dependent protein kinase A (PKA) phosphorylation of TAK1 at serine residue 412 
(Kobayashi, Mizoguchi et al. 2005).  Upon activation, TAK1 promotes the activation of p38 
and JNK MAPK by phosphorylating MKK3/6 and MKK4 respectively (Raman, Chen et al. 
2007).  TAK1 also plays a central role in NF-κB activation through direct phosphorylation of 
IKKβ (Wang, Deng et al. 2001).   
     Deregulated TAK1 signaling has been linked to constitutive IKK and NF-κB activity in 
various human cancer cell lines (Jackson-Bernitsas, Ichikawa et al. 2007; Xie, Wang et al. 
2009).  A potential role for TAK1 in mediating constitutive NF-κB activity in pancreatic 
cancer cells has yet to be characterized.  In this report, we investigate the status of basal 
TAK1 activity in a panel of pancreatic cancer cells and determine its role in driving 
constitutive NF-κB signaling, cell proliferation, and survival.  Moreover, we explore a 
potential regulatory link between GSK-3 and TAK1, and propose that constitutive NF-κB 
activity is driven by a unique GSK-3-TAK1-IKK signaling cascade.  Collectively, these data 
provide new insight in constitutive NF-κB regulation in pancreatic cancer, and establishes 
GSK-3 and TAK1 as emerging therapeutic targets. 
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3.3 Materials and Methods
 
     Cell culture and reagents.  Panc-1 (CRL-1496), MiaPaCa-2 (CRL-1420), BXPC3 (CRL-
1687), and Capan-1 (HTB-79) were obtained from the American Type Culture Collection 
(ATCC) (Manassas, VA).  Cells were maintained in complete growth medium recommended 
by ATCC and supplemented with 100 units/ml penicillin/ streptomycin.  Human pancreatic 
ductal epithelial cell line (HPDE6) was a generous gift from Dr. Channing Der (University of 
North Carolina at Chapel Hill, Chapel Hill, NC) and was maintained in keratinocyte serum-
free growth medium.  All cell culture reagents were obtained from Invitrogen (Carlsbad, 
CA).  The following antibodies were purchased from Cell Signaling (Beverly, MA):  
phospho-IKK α/β (Ser176/180), phospho-MKK3/6 (Ser189/207), MKK6, phospho-p65 
(Ser536), phospho-TAK1 (Ser412), phospho-TAK1 (Thr184/187), TAB1, and Flag-tag.  The 
following antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA):  
GSK-3α/β  (SC-7291), TAK1 (SC-7162), p65 (SC-109), β-tubulin (SC-9104), and GAPDH 
(SC-25778).  IKKα clone 14A231 antibody was obtained from Upstate Biotechnology (Lake 
Placid, NY).  Flag-tag (M2) antibody was purchased from Sigma-Aldrich (St. Louis, MO).  
PKA inhibitors (H-89 Dihydrochloride and Myristoylated PKI 14-22 amide) were purchased 
from Cell Signaling (Beverly, MA) and EMD Chemicals (La Jolla, CA) respectively.  GSK-3 
inhibitor (AR-A014481) was purchased from Sigma-Aldrich (St. Louis, MO). 
     Expression plasmids.  Flag-tagged, wild-type and dominant-negative (K63A) TAK1 
plasmids were a generous gift from Dr. Derek Abbott (Abbott, Yang et al. 2007).  TAK 
(serine 412 to alanine) mutagenesis was performed on the wild-type TAK1 plasmid using the 
QuikChange II Site-Directed Mutagenesis kit (La Jolla, CA) in accordance to manufacturer’s 
instructions.  Flag-tagged TAB1 plasmid was a generous gift from Dr. Jun Ninomiya-Tsuji 
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(North Carolina State University, Raleigh, NC).  Transient transfections were performed 
overnight with Lipofectamine LTX (Invitrogen, Carlsbad, CA) according to manufacturer’s 
instructions. 
     Small RNA interference.  The following human siRNA (siGenome SMARTpool) was 
purchased from Dharmacon (Layfayette, CO) as a pool of four annealed double-stranded 
RNA oligonucleotides:  MAP3K7 (M-003790-06), RELA (M-003533-02), GSK-3α (M-
003009-01), GSK-3β (M-003010-03), and non-targeting control #3 (D001201-03).  
Dharmafect 1 transfection reagent (Layfayette, CO) was used to transfect 100nM siRNA 
according to manufacturer’s instruction. 
     Western blot analysis and co-immunoprecipitation.  Whole-cell lysates were prepared 
on ice using Mammalian Protein Extraction Reagent (M-PER) (Pierce Biotechnology, 
Rockford, IL) supplemented with 1mM dithiothreitol (DTT), 1X protease inhibitor cocktail 
(Roche Applied Science, Indianapolis, IN), and 1X phosphatase inhibitor cocktail 1 (Sigma-
Aldrich, St. Louis, MO).  Protein concentrations were quantified by Bradford assay reagent 
(Bio-Rad Laboratories, Hercules, CA) and analyzed by SDS-PAGE as previously described 
(Wilson and Baldwin 2008).  Co-immunoprecipitation was performed as previously 
described (Sakurai, Miyoshi et al. 1999). 
     NF-κB DNA binding ELISA.  Nuclear extracts were harvested as previously described 
(Steinbrecher, Wilson et al. 2005).  Relative p65 DNA binding was quantified using the 
TransAM NF-κB transcription factor assay kit (Active Motif, Carlsbad, CA) in accordance to 
manufacturer’s instructions.  Samples were measured in triplicate at 450nm wavelength on a 
Versamax Microplate Reader (Molecular Devices Corp., Sunnyvale, CA). 
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     3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS tetrazolium) cellular proliferation assay.  Cells were transiently 
transfected with siRNA as described above and cellular proliferation was measured at the 
indicated times post-transfection using the CellTiter 96 Aqueous solution (MTS tetrazolium 
compound) in accordance with the manufacturer’s instructions (Promega, Madison, WI).  
Samples were measured in triplicate at 490nm wavelength on a Versamax Microplate Reader 
(Molecular Devices Corp., Sunnyvale, CA). 
     Luminescent-based caspase-3/7 activity assay.  Relative caspase-3/7 activity was 
measured using the Caspase-Glo 3/7 assay (Promega, Madison, WI) as previously described 
(Wilson and Baldwin 2008).  Relative light units were measured in triplicate on an Lmax 
Microplate Luminometer (Molecular Devices Corp., Sunnyvale, CA). 
     Dual-luciferase reporter assay.  Cells were transiently transfected with wild-type or 
mutant TAK1 plasmids as indicated above.  In addition, cells were co-transfected with an 
NF-κB-responsive luciferase reporter and a pRL-TK Renilla luciferase reporter (Promega, 
Madison, WI) using Lipofectamine LTX (Invitrogen, Carlsbad, CA).  Relative reporter 
activity was measured in triplicate using the Dual-Luciferase Assay System protocol 
(Promega, Madison, WI) as previously described (Wilson and Baldwin 2008). 
     Non-radioactive PKA activity assay.  PKA activity was measured using the Non-
radioactive Protein Kinase Assay Kit (EMD Chemicals, La Jolla, CA) according to 
manufacturer’s instructions.  In brief, cell lysates were mixed with kinase buffer (25mM 
Tris-HCl, 5mM β-mercaptoethanol, 3mM MgCl2, 1mM EGTA, 0.5mM EDTA, and 0.1mM 
ATP, pH 7.0) then incubated in a 96-well plate coated with PKA pseudosubstrate peptide.  A 
biotinylated monoclonal antibody was used to detect PKA-dependent peptide 
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phosphorylation, and horseradish peroxidase conjugated streptavidin antibody was used to 
quantitate phosphorylation levels.  Samples were measured in triplicate at 492 nm on a 
Versamax Microplate Reader (Molecular Devices Corp., Sunnyvale, CA).    
     Statistical analysis.  Statistical analysis of data was performed with Prism software 
(GraphPad Software, Inc. San Diego, CA).  An unpaired t test was used to evaluate 
differences between group means.  P values less than 0.05 were considered to be statistically 
different. 
 
3.4 Results 
 
     TAK1 is constitutively active in pancreatic cancer cells.  The phosphorylation of TAK1 
at threonine 184/187 (Yu, Ge et al. 2008) and serine 412 (Kobayashi, Mizoguchi et al. 2005) 
has been associated with TAK1 activity.  To determine whether TAK1 is active in pancreatic 
cancer, we examined the status of TAK1 phosphorylation in a panel of pancreatic cancer cell 
lines (Panc-1, MiaPaCa-2, BXPC3, and CaPan1) by western blot analysis.  As a control, we 
also measured TAK1 phosphorylation in an immortalized, human pancreatic ductal epithelial 
cell line (HPDE6).  Relative to HPDE6 cells, we observed a significant increase in 
phosphorylation of TAK1 at serine 412.  Moreover, TAK1 phosphorylation at threonine 184/ 
187 was also elevated, but to a lesser degree than serine 412 (Fig. 3.1).  To confirm TAK1 
activity, we also measured the phosphorylation of known TAK1 substrates (IKK and 
MKK3/6). IKK phosphorylation (serine 176/180) was elevated in the pancreatic cancer cell 
lines with the highest levels in Panc-1 and CaPan-1 cells (Fig. 3.1).  Notably, these data are 
consistent with previous reports of constitutive IKK and NF-κB activity in pancreatic cancer 
cell lines (Liptay, Weber et al. 2003; Li, Aggarwal et al. 2004).  Similarly, we also detected 
increased levels of MKK3/6 (serine 189/207) phosphorylation in the pancreatic cancer cell 
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lines relative to HPDE6 cells (Fig. 3.1).  Overall, these data provide initial evidence of 
constitutive TAK1 activity in pancreatic cancer cell lines. 
     TAK1 depletion down-regulates pro-survival NF-κB activity in pancreatic cancer 
cells.  We previously reported that IKK mediates constitutive NF-κB activity in pancreatic 
cancer cell lines (Panc-1 and MiaPaCa-2) (Wilson and Baldwin 2008).  To determine 
whether this activity is dependent on TAK1, we measured the effects of TAK1 depletion on 
constitutive IKK substrate phosphorylation.  Panc-1 and MiaPaCa-2 cells were transiently 
transfected with TAK1-specific siRNA for 48 hours. TAK1 knock-down resulted in 
significant depletion of TAK1 protein levels relative to non-targeting control (Fig. 3.2A).  
We observe diminished phosphorylation of the IKK substrate (IκBα at serine 32/36) 
following TAK1 depletion in Panc-1 and MiaPaCa-2 cells (Fig. 3.2A).  The stabilization of 
total IκBα levels following TAK1 knock-down also indicated reduced phosphorylation and 
proteasomal degradation IκBα.  IKK is also known to phosphorylate p65/RelA at serine 536 
to promote NF-κB transcriptional activity at target gene promoters (Mattioli, Sebald et al. 
2004).  Similar to IκBα, TAK1 knock-down resulted in diminished p65 phosphorylation 
relative to non-targeting control (Fig. 3.2A).  Moreover, these results correlated with reduced 
p65 DNA binding following TAK1 depletion (Fig. 3.2B).  Taken together, these results 
indicate that TAK1 plays a key role in regulating constitutive IKK and subsequent NF-κB 
activity in pancreatic cancer cells. 
     To determine the functional significance of TAK1-mediated NF-κB activity, we examined 
the effect of TAK1 depletion on pancreatic cancer cell growth/survival.  MiaPaCa-2 cells 
were transiently transfected with TAK1-specific siRNA and cell proliferation was measured 
at 48, 72, and 96 hours post-transfection.  TAK1 depletion significantly reduced cell 
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proliferation relative to non-targeting control throughout the time-course (Fig. 3.2C).  
Moreover, these results were similar to the growth suppression observed following the 
knock-down of the NF-κB subunit, p65/RelA (Fig. 3.2C).  Next, we determined whether this 
abrogated cell growth correlated with the induction of apoptosis as measured by caspase-3/ 7 
activity.  MiaPaCa-2 cells were transiently transfected with TAK1 and p65-specific siRNA 
for 48 hours and caspase-3/7 activity was measured.  We observed an increase in caspase-3/ 
7 activity following knock-down of either TAK1 or p65 (Fig. 3.2D).  Thus, these data 
provide evidence that TAK1 is active in pancreatic cancer cells and mediates constitutive 
pro-survival NF-κB signaling. 
     Blockade of GSK-3 suppresses constitutive phosphorylation of TAK1 at serine 412.  
We proposed that GSK-3 drives constitutive IKK and NF-κB activity in pancreatic cancer 
cell lines through an unknown mechanism (Wilson and Baldwin 2008).  To determine 
whether GSK-3 potentiates TAK1-dependent NF-κB signaling, we measured the effect of 
GSK-3 inhibition (AR-A014418) on TAK1 phosphorylation.  Panc-1 and MiaPaCa-2 cells 
were treated for 24 hours with AR-A014418 and TAK1 phosphorylation at serine 412 and 
threonine 184/187 was measured by western blot analysis.  Interestingly, we observed a 
reduction in serine 412 phosphorylation in both cell lines with the maximum effect seen in 
Panc-1 cells (Fig. 3.3A).  Notably, TAK1 phosphorylation at threonine 184/ 187 was not 
effected by GSK-3 inhibition.  Next, we examined whether the reduced serine 412 
phosphorylation of TAK1 correlated with decrease substrate phosphorylation of IKK and 
p65.  Consistent with our previous data (Wilson and Baldwin 2008), GSK-3 inhibition also 
suppressed IKK and p65 phosphorylation in Panc-1 and MiaPaCa-2 cells (Fig. 3.3A).   
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     AR-A014481 targets the inhibition of GSK-3α and GSK-3β, but potential off-target 
effects from this inhibitor cannot be ruled out.  Therefore, we measured the effects of GSK-
3α/β depletion on TAK1 phosphorylation and subsequent NF-κB activity.  Panc-1 and 
MiaPaca-2 cells were transiently transfected with GSK-3α/β-specific siRNA for 48 hours 
and significant reduction in GSK-3 protein levels were observed relative to non-targeting 
siRNA control (Fig. 3.3B).  Consistent with GSK-3 inhibition, GSK-3α/β knock-down 
resulted in the downregulation of TAK1 phosphorylation at serine 412 and not threonine 184/ 
187 (Fig. 3.3B).  Furthermore, the reduced TAK1 phosphorylation at serine 412 correlated 
with decreased phosphorylation of IKK and p65 in both cell lines (Fig. 3.3B).  Overall, these 
data provide initial evidence that links GSK-3 to constitutive NF-κB signaling in pancreatic 
cancer cells via phosphorylation of TAK1 at serine 412.   
     TAK1 phosphorylation at serine 412 is necessary to induce IKK phosphorylation.  
The phosphorylation of TAK1 at serine 412 by PKA was reported to enhance cytokine-
induced NF-κB activity in RAW264.7 macrophage cells (Kobayashi, Mizoguchi et al. 2005).  
To determine whether this TAK1 phosphorylation is also required to enhance NF-κB activity 
in pancreatic cancer cells, we utilized ectopic expression of a serine 412 to alanine TAK1 
point mutant.  To confirm TAK1 mutagenesis, Panc-1 cells were transiently transfected with 
flag-tagged, wild-type and mutant TAK1 (S412A), then stimulated with forskolin to induced 
PKA-dependent TAK1 phosphorylation.  Following flag-tagged TAK1 immunoprecipitation, 
we confirmed that TAK1 (S412A) was deficient in basal and inducible phosphorylation 
relative to wild-type TAK1 (Fig. 3.4A).  Since ectopic expression of TAK1 alone is not 
sufficient to induced NF-κB activity, TAK1 must be co-expressed with TAK1 binding 
protein (TAB1) (Kishimoto, Matsumoto et al. 2000). To determine whether S412 TAK1 
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phosphorylation is required to induce NF-κB signaling, we measured basal IKK 
phosphorylation upon TAK1 and TAB1 co-expression in Panc-1 cells.  Co-expression of 
TAB1 with wild-type TAK1 significantly induced IKK phosphorylation relative to vector 
control (Fig. 3.4B).  In contrast, TAK1 (S412A) failed to induce IKK phosphorylation (Fig. 
3.4B).  Furthermore, this result was consistent with the expression of kinase dead TAK1 
(K63A) mutant and suggests serine 412 phosphorylation promotes TAK1 catalytic activity 
against IKK (Fig. 3.4B).  Next, we measured the ability of TAK1 (S412A) to induce an NF-
κB luciferase reporter upon TAB1 co-expression.  Consistent with IKK phosphorylation, 
wild-type TAK1 expression significantly induced NF-κB reporter activity while kinase dead 
TAK1 (K63A) was deficient in this response (Fig. 3.4C).  However, the TAK1 (S412A) 
mutant retained the ability to induce NF-κB reporter activity, but the level of activity was 
significantly less than wild-type TAK1 (Fig. 3.4C).  Thus, these data suggests that TAK1 
phosphorylation at serine 412 plays a role in promoting IKK phosphorylation, but is only 
partially required to induce NF-κB activity.   
     TAK1 phosphorylation at serine 412 is PKA-dependent.  Cyclic-AMP-dependent PKA 
was previously reported to be constitutively active in pancreatic cancer cells (Farrow, 
Rychahou et al. 2003).  Therefore, we investigated whether constitutive TAK1 (S412) and 
IKK phosphorylation was dependent on PKA activity.  Panc-1 cells were treated for 30 
minutes with increasing concentrations (1, 15, 30 μM) of forskolin to measure the ability of 
PKA to enhance basal TAK1 and IKK phosphorylation.  Forskolin treatment resulted in a 
dose-dependent increase in PKA activity relative to vehicle control (Fig. 3.5A)  Moreover, 
the increase in PKA activity following forskolin treatment correlated with enhanced TAK1 
and IKK phosphorylation (Fig. 3.5B).  Next, we examined whether constitutive TAK1 and 
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IKK phosphorylation was maintained by PKA activity in pancreatic cancer cells.  Panc-1 
cells were treated with the increasing concentrations of the PKA inhibitor (H89) for 24 hours.  
Consistent with a previous report (Farrow, Rychahou et al. 2003), H89 treatment resulted in a 
dose-dependent reduction of basal PKA activity (Fig. 3.5C).  In addition, we observed 
decreased phosphorylation of TAK and IKK following H89 treatment with the maximum 
effect seen at 30μM (Fig. 3.5D).  However, the minor decrease in PKA activity following 
1μM H89 did not correlated with the dramatic loss of TAK1 phosphorylation seen at the 
same dose. Potential off-target effects of H89-mediated PKA inhibition could explain these 
results (see discussion).  Overall, these data confirms PKA as a TAK1 (S412) kinase and 
suggests a role for PKA in regulating TAK1 and subsequent IKK activity in pancreatic 
cancer cells.   
     GSK-3 is not required for forskolin-induced TAK1 phosphorylation at serine 412.  
Our data suggests that GSK-3 promotes constitutive IKK and NF-κB activity through the 
phosphorylation of TAK1 at serine 412 (Fig. 3.3).  However, the link between GSK-3 and 
TAK1 is unclear since the TAK1 (S412) motif (NGQPRRRSIQDLTVT) does not fit the 
consensus substrate motif of GSK-3 (S/T-XXX-S/T).  Therefore, we investigated whether 
GSK-3 indirectly regulates basal and inducible TAK1 phosphorylation through PKA.  Panc-1 
cells were pre-treated with the GSK-3 inhibitor (AR-A014418) or vehicle control (DMSO) 
for 24 hours, and then treated with increasing concentration of forskolin for 30 minutes.  
GSK-3 inhibition decreased overall levels of TAK1 (S412) phosphorylation relative to 
vehicle control (Fig.3.6A).  However, forskolin treatment was still able to enhance TAK1 
phosphorylation in a dose-dependent manner following GSK-3 inhibition (Fig. 3.6A).  In 
contrast, forskolin-induced IKK phosphorylation was attenuated following treatment with 
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AR-A014418 (Fig. 3.6A).  Next, we examined whether GSK-3 inhibition could suppress 
basal or forskolin-induced PKA activity in Panc-1 cells.  We observe no significant change in 
basal PKA activity following GSK-3 inhibition (Fig. 3.6B).  In addition, pre-treatment with 
AR-A014418 slightly enhanced forskolin-induced PKA activity relative to vehicle control 
(Fig. 3.6B).  Collectively, these data suggests a model for forskolin-induced and constitutive 
TAK1 (S412) phosphorylation (Fig.3.7): (1) PKA-dependent TAK1 phosphorylation in 
response to forskolin and (2) GSK-3-dependent basal TAK1 phosphorylation that does not 
require PKA (Fig. 3.7). We propose that constitutive NF-κB activity in pancreatic cancer 
cells is driven by a novel GSK-3-TAK1-IKK signaling cascade (Fig. 3.7).  However, the 
regulatory link between GSK-3 and TAK1 (S412) phosphorylation remains to be discovered.  
3.5 Discussion
     The molecular mechanism underlying constitutive NF-κB activity in pancreatic cancer is 
complex and utilizes crosstalk from various pathways.  Current research efforts have focused 
on expanding our knowledge of these pathways to identify novel therapeutic targets (Zhang 
and Rigas 2006). GSK-3 has been implicated in regulating constitutive NF-κB activity in 
pancreatic cancer (Ougolkov, Fernandez-Zapico et al. 2005; Ougolkov, Fernandez-Zapico et 
al. 2006; Wilson and Baldwin 2008).  Moreover, this multi-tasking kinase has emerged over 
the years as a promising therapeutic target for pancreatic cancer and many other human 
malignancies (Ougolkov, Bone et al. 2007; Rinnab, Schutz et al. 2008; Wang, Smith et al. 
2008; Zhou, Uddin et al. 2008).  Nevertheless, the mechanism by which GSK-3 drives 
constitutive NF-κB activity in pancreatic cancer remains elusive.  We previously reported the 
GSK-3 signals through IKK to mediate constitutive NF-κB signaling in pancreatic cancer 
cells (Wilson and Baldwin 2008).  In this report, we provide the first evidence that TAK1 is 
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constitutively active pancreatic cancer cell lines (Fig. 3.1) and propose that GSK-3 and IKK 
are functionally linked through the phosphorylation of TAK1 at serine 412 (Fig.3.7). 
     The phosphorylation of TAK1 at serine 412 was initially reported to enhance RANKL-
induced NF-κB activity and osteoclast differentiation in response to prostaglandin E2 
(PGE2) (Kobayashi, Mizoguchi et al. 2005).  This novel phosphorylation on TAK1 was 
shown to be driven by cyclic AMP-dependent activation of PKA (Kobayashi, Mizoguchi et 
al. 2005).  We demonstrated that TAK1 (S412) phosphorylation is significantly elevated in 
pancreatic cancer cells and may be responsible for driving constitutive NF-κB activity (Fig. 
3.1).  Co-expression of TAK1 (S412A) mutant with TAB1 failed to enhance basal levels of 
IKK phosphorylation relative to wild-type TAK1.  This data is consistent with a previous 
report that showed TAK1 (S412A) expression attenuated RANKL, LPS, and TNF-α-induced 
IκBα degradation (Kobayashi, Mizoguchi et al. 2005).  Despite being defective in inducing 
IKK phosphorylation, TAK1 (S412A) mutant retained partial ability to induced NF-κB 
luciferase activity.  This result would suggest that TAK (S412A) mutant can signal to NF-κB 
through a mechanism that is not dependent on IKK activity.  We note that the TAK1 (S412) 
phosphorylation site resides outside the kinase domain and within the C-terminal TAB2/3 
binding domain of TAK1.  TAB2 and TAB3 associate with TAK1 and promotes its 
recruitment to K63-linked polyubiquitinated signaling adapters in response to stimuli 
(Kanayama, Seth et al. 2004; Besse, Lamothe et al. 2007).  Therefore, TAK1 (S412) 
phosphorylation could mediate TAB2/3 binding and subsequent TAK signaling.  However, 
evidence showed that enhanced TAK1 (S412) phosphorylation by prostaglandin E2 failed to 
change TAK1-TAB2/3 association in response to RANKL (Kobayashi, Mizoguchi et al. 
2005).  Our knowledge of TAK (S412) phosphorylation is limited and further studies are 
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needed to fully elucidate its role in mediating constitutive TAK1 and NF-κB activity in 
pancreatic cancer cells.    
     In this study, we explored the potential mechanisms that drive TAK (S412) 
phosphorylation and subsequent downstream activation of IKK in pancreatic cancer cells.  
Currently, PKA is the only known kinase to phosphorylate TAK1 at serine 412 (Kobayashi, 
Mizoguchi et al. 2005).  Our data also suggest that PKA can function as a TAK (S412) 
kinase in response to forskolin treatment (Fig. 3.5).  Interestingly, there is also evidence that 
links PKA activity to pancreatic cancer. The pancreatic cancer cell line (JF-305) was shown 
to secrete prostaglandin E2 which facilitated PKA-dependent production of cyclooxygenase-
2 (COX2), as well as, cell proliferation, and survival (Wu, Yi et al. 2005).  Moreover, the 
pharmacological PKA inhibitor (H89) was shown to suppress cell growth and induce 
apoptosis in Panc-1 and MiaPaCa-2 cells (Farrow, Rychahou et al. 2003).  Our data indicates 
that H89-mediated PKA inhibition also results in decreased TAK1 (S412) and IKK 
phosphorylation in Panc-1 cells (Fig. 3.5).  We note that the degree of H89-mediated PKA 
inhibition was not proportional to the levels of TAK1 (S412) and IKK phosphorylation (Fig. 
3.5).  Although H89 is an effective PKA inhibitor, several off-target effects have been 
associated with this compound (Lochner and Moolman 2006).  For example, H89 has been 
shown to target PKC, PKG, S6K, and AMPK (Lochner and Moolman 2006).  Therefore, 
these off-targets need to be taken into consideration when measuring H89-mediated 
suppression of TAK1 (S412) and IKK phosphorylation.  Further studies are needed to rule 
out these H89 off-targets as potential TAK1 (S412) kinases.  Moreover, the use of alternative 
PKA inhibitors is necessary in establishing the role of PKA in regulating constitutive TAK1 
(S412) and IKK phosphorylation in pancreatic cancer cells.  
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     Our previous work implicated GSK-3 in regulating constitutive IKK activity and pro-
survival NF-κB signaling in pancreatic caner cells (Wilson and Baldwin 2008).  Here, we 
discovered that GSK-3 may be linked to IKK through the phosphorylation of TAK1 at serine 
412 (Fig. 3.3).  Thus, we proposed that constitutive NF-κB activity in pancreatic cancer cells 
is driven by a novel GSK-3-TAK1-IKK signaling cascade.  We note that the TAK (S412) 
phosphorylation site (NGQPRRRSIQDLTVT) does not match the consensus GSK-3 
substrate recognition motif (S/T-XXX-S/T).  Therefore, we investigated indirect mechanisms 
of GSK-3-dependent TAK1 phosphorylation.  Since PKA plays a key role in TAK1 (S412) 
phosphorylation (Kobayashi, Mizoguchi et al. 2005), we asked whether GSK-3 was required 
for PKA-dependent phosphorylation of TAK1 (S412) and IKK phosphorylation.  Our data 
provides a model for both forskolin-induced and constitutive regulation of TAK1 (S412) 
phosphorylation in pancreatic cancers cells (Fig. 3.7).  Indeed, PKA prompts the induction of 
TAK1 (S412) in response to forskolin.  However, we also identified a novel mechanism by 
which GSK-3 drives constitutive levels of TAK1 (S412) and IKK phosphorylation 
independent of PKA.  Additional studies are needed to discover the missing link between 
GSK-3 and TAK1. These efforts will be dependent on finding alternative TAK1 (S412) 
kinases and elucidates their regulation by GSK-3.  As indicated above, the off-target kinases 
of H89 may serve as potential candidates for identifying alternative TAK1 (S412) kinases.   
     Overall, our data underscores the complexity underlying TAK1-mediated NF-κB activity 
in pancreatic cancer cells and emphasizes the need to explore alternative mechanisms of 
GSK-3-dependent TAK1 (S412) phosphorylation.  Moreover, this report provides additional 
evidence that implicates GSK-3 and TAK1 as emerging therapeutic targets in pancreatic 
cancer. 
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Figure 3.1.  TAK1 is constitutively active in pancreatic cancer cells.  Whole cell lysates 
were harvested from human pancreatic cancer cell line (Panc-1, MiaPaCa-2, BXPC3, and 
CaPan-1) and an immortalized human pancreatic ductal epithelial cell line (HPDE6).  
Western blot analysis was performed with the indicated antibodies. The phosphorylation of 
TAK1 (Ser412 and Thr184/ 187), MKK3/6 (Ser189/207), and IKKα/β (Ser176/180) are 
indicative of TAK1 activity. 
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Figure 3.2.  TAK1 mediates pro-survival NF-κB activity in pancreatic cancer cells.  (A) 
Panc-1 and MiaPaCa-2 cells were transiently transfected with non-targeting (siCTRL) or 
TAK1 siRNA for 48 hours.  Whole cell lysate were harvested and western blot analysis was 
performed.  (B) Panc-1 and MiaPaCa-2 cells were transfected with siRNA as indicated above 
and nuclear extracts were harvested.  An NF-κB (p65) DNA binding ELISA was performed 
to measure relative p65 activity. Samples were measured in triplicate and normalized to 
siCTRL for each cell line.  Asterisk indicates statistical difference relative to siCTRL (P < 
0.05).  (C) MiaPaCa-2 cells were transfected with siRNA as indicated above and cell 
viability was measured at the indicated times post-transfection.  Samples were measured in 
triplicate and normalized to untransfected cells.  Asterisk indicates statistical difference 
relative to siCTRL at each time point (P < 0.05).  (D)  MiaPaCa-2 cells were transfected with 
siRNA for 48 hours.  Apoptosis was measured using a luminescent-based caspase-3/7 assay.  
Samples were measured in triplicate and normalized to siCTRL.  Asterisk indicates statistical 
difference relative to siCTRL (P < 0.05). 
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Figure 3.3.  Blockade of GSK-3 suppresses constitutive phosphorylation of TAK1 at 
serine 412.  (A) Panc-1 and MiaPaCa-2 cells were treated for 24 hours with 25μM GSK-3 
inhibitor (AR-A014481), whole cell lysates were harvested, and western blot analysis was 
performed with the indicated antibodies.  (B) Panc-1 and MiaPaCa-2 cells were transiently 
transfected with non-targeting control (siCTRL) or siRNA targeting GSK-3α and GSK-3β 
(siGSK-3α/β) for 48 hours.  Whole cell lysates were harvested and western blot analysis was 
performed as indicated above. 
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Figure 3.4.  TAK1 phosphorylation at serine 412 is necessary to induce IKK 
phosphorylation.  (A) Panc-1 cells were transiently transfected with flagged wild-type or 
mutant (S412A) TAK1 for 24 hours.  Cells were treated with 30μM Forskolin or vehicle 
control (DMSO).  Whole cell extracts were harvested.  Samples were immunoprecipitated 
with flag antibody or IgG control then analyzed by western blot with the indicated 
antibodies.  (B) Panc-1 cells were transiently co-transfected with TAB1 and either vector 
control, wild-type TAK1, kinase dead TAK1 (K63A), or mutant TAK1 (S412A).  Whole cell 
lysates were harvested and western blot analysis was performed.  (C) Panc-1 cells were co-
transfected as indicated above along with 3X NF-κB luciferase and renilla reporter.  NF-κB 
reporter activity was measured in triplicate and indicated as fold-induction relative to vector 
control.  Asterisk indicates statistical difference relative to wild-type TAK1 induction (P < 
0.05). 
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Figure 3.5.  TAK1 phosphorylation at serine 412 is PKA-dependent.  (A) Panc-1 cells 
nd 
 
were treated with vehicle control (DMSO) or the increasing concentrations (1μM, 15μM, a
30μM) of forskolin for 24 hours.  Whole cell lysates were harvested and PKA activity was 
measured using a non-radioactive PKA ELISA assay.  Samples were measured in triplicate 
and normalized to DMSO.  (B) Whole cell lysates from (A) were analyzed by western blot 
with indicated antibodies.  (C) Panc-1 cells were treated with vehicle control (DMSO) or the
increasing concentrations (1μM, 15μM, and 30μM) of PKA inhibitor (H89) for 24 hours.  
(C) PKA activity (D) western blot analysis was performed as indicated above.  Asterisk 
indicates statistical difference relative to DMSO (P < 0.05).  
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Figure 3.6.  GSK-3 is not required for forskolin-induced TAK1 phosphorylation at 
rine 412. (A) Panc-1 cells were pre-treated with vehicle control or 30μM GSK-3 inhibitor 
μM, 
 
se
(AR-A014418) for 24 hours.  Cells were treated with increasing concentrations (1μM, 15
and 30μM) of forskolin for 30 minutes, whole cell lysates were harvested, and western blot 
analysis was performed with the indicated antibodies.  (B) PKA activity was measured in the 
whole cell lysates from (A) using a non-radioactive PKA ELISA assay.  Samples were 
measured in triplicate and normalized to DMSO.  Asterisk indicates statistical difference 
relative to DMSO in each group (P < 0.05).      
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Figure 3.7.  Model for inducible and constitutive TAK (S412) phosphorylation in 
pancreatic cancer cells.  We propose that the mechanism by which GSK-3 regulates 
onstitutive TAK (S412) phosphorylation in pancreatic cancer is distinct from PKA-induced 
vates 
 
c
TAK1 phosphorylation in response to forskolin.  GSK-3 drives TAK1 activity through 
indirect (dashed arrow) regulation of TAK1 phosphorylation at serine 412.  TAK1 acti
downstream IKK phosphorylation at serine 176/180, and subsequent IκBα phosphorylation 
(serine 32/36) and degradation. As a result, pro-survival NF-κB is activated. Forskolin 
increases intercellular levels of cyclic AMP and facilitates PKA-dependent TAK1 (S412) 
phosphorylation independent of GSK-3. 
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CHAPTER IV 
 
 
CONCLUSIONS & FUTURE DIRECTIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1 Conclusions and future directions 
     For more than a decade, the link between GSK-3 and cancer has been dominated by the 
paradigm of GSK-3 functioning as a tumor suppressor (Lustig and Behrens 2003).  This 
paradigm is based on the Wnt/β-catenin pathway in human colorectal cancer where GSK-3 
suppresses the oncogenic affect of β-catenin (Shakoori, Ougolkov et al. 2005).  Recently, this 
paradigm has been challenged by several reports that implicate a potential oncogenic role for 
GSK-3 in pancreatic cancer (Ougolkov, Fernandez-Zapico et al. 2005; Wilson and Baldwin 
2008), chronic lymphocytic B-cells (Ougolkov, Bone et al. 2007), prostate cancer (Rinnab, 
Schutz et al. 2008), myeloid-lymphoid leukemia (MLL)(Wang, Smith et al. 2008), and 
multiple myeloma (Zhou, Uddin et al. 2008).  Indeed, GSK-3 is now emerging as a 
therapeutic target for various human malignancies in part for its role in regulating 
constitutive NF-κB activity (Ougolkov and Billadeau 2006).  Thus, there is a confounding 
question centered on whether GSK-3 is an oncogene or tumor suppressor, and what adverse 
affects GSK-3 inhibitors will have as a cancer therapy in the clinics.  The fact of the matter 
remains that cancer is a complex, heterogeneous disease.  Therefore, the role GSK-3 plays in 
cancer may be dependent on cancer cell type, tumor microenvironment, genetic background, 
etc.   
     The previous chapters underscore the oncogenic role GSK-3 plays in pancreatic cancer.  
Consistent with previous reports (Ougolkov, Fernandez-Zapico et al. 2005; Ougolkov, 
Fernandez-Zapico et al. 2006), our data indicates that GSK-3 drives constitutive, pro-survival 
NF-κB activity in pancreatic cancer cell lines (Panc-1 and MiaPaCa-2).  The primary focus 
of this project was to characterize GSK-3-dependent regulation of constitutive NF-κB 
activity.  Importantly, we provide initial evidence that GSK-3 facilitates pro-survival NF-κB 
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signaling by maintaining constitutive IKK activity.  Although the link between GSK-3 and 
IKK is not established, we explored a potential mechanism that utilizes a known regulator of 
IKK, TAK1.  Our data suggests that TAK1 is constitutively active in pancreatic cancer cells 
and plays a role in maintaining NF-κB signaling.  Importantly, we hypothesize that GSK-3 
may be linked to constitutive IKK and NF-κB through the novel phosphorylation of TAK1 at 
serine 412.  However, further evidence is needed to establish that constitutive NF-κB activity 
in pancreatic cancer can be mediated through this GSK-3-TAK-IKK signaling cascade.   The 
following questions should be addressed to support this model:  (1) Is TAK1 phosphorylation 
at serine 412 essential for constitutive NF-κB activity in pancreatic cancer cells? (2) How 
does phosphorylation of TAK1 at serine 412 modulate TAK1 signaling?  (3) What is the link 
between GSK-3 and constitutive TAK phosphorylation at serine 412?  
     (1) Is TAK1 phosphorylation at serine 412 essential for constitutive NF-κB activity in 
pancreatic cancer cells?  TAK1 (S412) phosphorylation was originally discovered to 
enhance cytokine-induced NF-κB activity in response to prostaglandin E2 (Kobayashi, 
Mizoguchi et al. 2005).  However, the requirement for TAK1 (S412) phosphorylation in 
maintaining constitutive NF-κB activity in pancreatic cancer cells remains elusive.  The 
experiments presented in Figure 3.4 utilized TAK1-TAB1 co-expression to investigate the 
ability of TAK (S412A) mutant to induce IKK and NF-κB activity.  Although the TAK 
(S412A) mutant was deficient in inducing IKK phosphorylation, it still retained the ability to 
induce NF-κB reporter activity.  To explain this paradox, further experiments are needed to 
determine if TAK1-induced IKK is required for NF-κB activity in pancreatic cancer cells.  
Other read-outs of NF-κB activity (i.e. NF-κB target gene expression, NF-κB DNA binding, 
and NF-κB nuclear localization) should be explored to fully ascertain the effect of TAK1 
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(S412A) mutation on NF-κB signaling.  When interpreting these data, we must take into 
consideration that other oncogenic factors (i.e. KRAS and AKT) may be signaling to IKK 
and NF-κB through a TAK1-independent mechanism.  We must also take into account that 
ectopic expression of TAK1 creates an artificial system of NF-κB regulation that may not 
recapitulate how endogenous levels of TAK1 regulate constitutive NF-κB.   
     (2) How does phosphorylation of TAK1 as serine 412 modulate TAK1 signaling?  
The phosphorylation of TAK1 at serine 412 resides outside the catalytic domain and suggests 
that this phosphorylation event does not control overall TAK1 kinase activity.  Therefore, 
additional experiments are needed to fully understand how TAK (S412) phosphorylation 
controls TAK1 signaling.  Serine 412 resides in the C-terminal, TAB2/3 binding domains of 
TAK1.  The function of TAB2/3 is to promote the recruitment of TAK1 to K63-linked 
polyubiquitinated signaling adapters (i.e. TRAF6 and RIP1).  Thus, TAK1 (S412) 
phosphorylation could facilitate TAB2/3 binding and subsequent recruitment to these 
signaling adapters in pancreatic cancer cells.  To investigate this model, we must first 
determine whether TAK (S412A) mutant has a decreased affinity for TAB2/3.  Next, we 
should ascertain the status of K63-linked polyubiquitination on TRAF6 or RIP1 and 
determine whether endogenous TAK1 can associate with these signaling adapters.   
     (3) What is the link between GSK-3 and constitutive TAK phosphorylation at serine 
412 regulated?  We provide evidence that GSK-3 inhibition and knock-down correlate with 
the suppression of constitutive TAK1 (S412) phosphorylation in pancreatic cancer cells (Fig. 
3.3).  However, the link between GSK-3 and TAK1 requires further elucidation.  We 
hypothesized that GSK-3 indirectly regulates TAK1 (S412) phosphorylation.  The 
investigation of this regulatory mechanism is dependent on identifying potential TAK1 
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(S412) kinases.  PKA was discovered to induce TAK1 (S412) phosphorylation in response to 
prostaglandin E2 in RAW264.7 macrophage cells (Kobayashi, Mizoguchi et al. 2005).  
However, our data suggest that GSK-3 may control constitutive TAK (S412) phosphorylation 
in pancreatic cancer cells through a PKA-independent mechanism.  In Figure 3.5, the PKA 
inhibitor (H89) was used to investigate the role of PKA in regulating constitutive TAK1 
(S412) phosphorylation in pancreatic cancer cells.  Due to the off-target effects of H89, 
questions were raised about alternative kinases that can phosphorylate TAK1.  Additional 
experiments should explore the off-target effect of H89 and determine whether they could be 
regulated by GSK-3.  For example, protein kinase C (PKC) represents a potential alternative 
kinase that can phosphorylate TAK1 at serine 412.  Constitutive PKC activity has also been 
implicated in pancreatic cancer and is considered a therapeutic target (El-Rayes, Ali et al. 
2008).  Future experimentation should utilize selective PKC inhibitors to establish the role of 
this kinase in regulating constitutive TAK1 (S412) phosphorylation and downstream NF-κB 
signaling.  Importantly, these studies should determine whether the blockade of GSK-3 
affects PKC activity.   
     In addition to these immediate questions, this project also raises several fundamental 
questions regarding GSK-3-dependent NF-κB regulation.  (1) How is GSK-3 deregulated in 
pancreatic cancer?  (2) What is the normal physiological relationship between GSK-3 and 
TAK1 under inducible NF-κB conditions? (3) What role do nuclear GSK-3 and IKKα play 
in driving constitutive NF-κB activity in pancreatic cancer cells?  (4)  Is the activity of GSK-
3 and TAK1 required for pancreatic cancer progression in vivo? 
     (1) How is GSK-3 deregulated in pancreatic cancer? One of the main questions 
underlying oncogenic GSK-3 is determining how this kinase becomes deregulated in cancer.  
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Currently, there have been no cancer-related mutations associated with GSK-3.  Therefore, 
GSK-3 may be deregulated by aberrant upstream signaling pathways.  GSK-3 is a 
constitutively active kinase that is primarily known to be negatively regulated through 
phosphorylation at serine 9 (GSK-3β) and 21 (GSK-3α) (Doble and Woodgett 2003).  We 
observe basal phosphorylation of these inhibitory markers in pancreatic cancer cells (data not 
shown).  However, work from our lab and others suggest GSK-3 still retains the ability to 
activate NF-κB.  This evidence indicates that GSK-3-dependent regulation of constitutive 
NF-κB in pancreatic cancer is independent of inhibitory serine 9/21 phosphorylation.  
Importantly, we also observe that blockade of GSK-3 activity does not lead to the 
stabilization of β-catenin in pancreatic cancer cells (data not shown).  This may be due to 
constitutive activation of the Wnt pathway which sustains elevated levels of β-catenin. In 
fact, it was recently reported that pancreatic cancers have elevated expression of ataxia-
telangiectasia group D complementing gene (ATDC) (Wang, Heidt et al. 2009).  ATDC 
interacts with the negative regulator of GSK-3 (Disheveled-2) and drives β-catenin 
stabilization and oncogenesis (Wang, Heidt et al. 2009). Thus, there may be pools of GSK-3 
existing outside of the β-catenin “destruction complex” that promotes constitutive NF-κB.  
Nevertheless, further studies are needed to fully elucidate the context of GSK-3 deregulation 
in pancreatic cancer and its relationship with NF-κB pathway.   
     (2) What is the normal physiological relationship between GSK-3 and TAK1 under 
inducible NF-κB conditions?  NF-κB activation is a tightly regulated process that can be 
triggered by a variety of inflammatory stimuli.  We hypothesize in this project that NF-κB 
activity is driven by a novel GSK-3-TAK-IKK signaling cascade.  In order to broaden our 
understanding of this signaling event, it is important determine how this process is normally 
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regulated under physiological conditions.  Chapter 1 reviewed how GSK-3 and TAK1 play 
critical roles in crossregulating NF-κB activation upon inflammatory stimuli (i.e. TNF-α, IL-
1β, LPS).  However, the functional link between GSK-3 and TAK1 under these conditions 
remains to be investigated.  Work from our group and others suggests that GSK-3 mediates 
TNF-α-induced NF-κB activity at the transcriptional complex level (Hoeflich, Luo et al. 
2000; Steinbrecher, Wilson et al. 2005).  Additionally, we provide evidence  that GSK-3 
specifies NF-κB-dependent gene transcription at select promoters (Steinbrecher, Wilson et al. 
2005).  Interestingly, there is also evidence that p38 MAPK selectively regulates a subset of 
NF-κB regulated genes upon inflammatory stimulation (Saccani, Pantano et al. 2002).  This 
report suggests that p38 marks selected promoters for increased NF-κB recruitment by 
promoting histone H3 phosphorylation and phosphoacetylation (Saccani, Pantano et al. 
2002). Numerous reports have demonstrated the requirement of TAK1 for inducible p38 
activity upon inflammatory stimulation (Raman, Chen et al. 2007).  Therefore, future studies 
should investigate whether GSK-3 mediates TNF-α-induced TAK1 and subsequent p38 
activity.  Furthermore, these studies should utilize chromatin immunoprecipitation to 
determine whether GSK-3 and TAK1 are required for histone H3 post-translational 
modifications at select NF-κB-dependent promoters.  The exact mechanism of how GSK-3 
mediates inducible NF-κB activity has remained elusive over the past decade.  These 
proposed experiments will provide new insight into GSK-3-dependent NF-κB regulation and 
expand our understanding of the link between GSK-3 and TAK1. 
     (3) What role does nuclear GSK-3 and IKKα play in driving constitutive NF-κB 
activity in pancreatic cancer cells?   The previous chapters described a model by which 
GSK-3 mediates constitutive NF-κB activity within the cytoplasm of pancreatic cancer cells.  
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However, evidence suggests GSK-3β (Ougolkov, Fernandez-Zapico et al. 2006; Ougolkov, 
Bone et al. 2007) and IKKα (Anest, Hanson et al. 2003) can also function within the nucleus 
to mediate NF-κB transcriptional activity.  Characterization of GSK-3β revealed a nuclear 
localization sequence (NLS) within the kinase domain between amino acids 85 – 123 
(Meares and Jope 2007).  Moreover, loss of GSK-3β kinase activity was associated with 
decreased nuclear localization and proteasomal degradation of GSK-3β (Ougolkov, 
Fernandez-Zapico et al. 2006; Meares and Jope 2007).  A previous report demonstrated that 
GSK-3β was aberrantly accumulated in the nucleus of human pancreatic tumor tissues and 
pancreatic cancer cell lines (Ougolkov, Fernandez-Zapico et al. 2006).  The role of nuclear 
GSK-3α and GSK-3β in regulating constitutive NF-κB activity in pancreatic cancers remains 
unclear.  However, evidence in chronic lymphocytic leukemia cells suggest that GSK-3 
inhibition can suppress NF-κB recruitment to target gene promoters through an epigenetic 
silencing mechanism (Ougolkov, Bone et al. 2007).  IKKα has also been reported to 
translocate to the nucleus and promote chromatin remodeling at NF-κB target gene 
promoters (Anest, Hanson et al. 2003).  Importantly, the role of nuclear IKKα in regulating 
constitutive NF-κB activity pancreatic cancer cells remains uncharacterized.  Preliminary 
data from our group indicates that IKKα, GSK-3α, and GSK-3β are present in the nucleus of 
human pancreatic cancer cells and tissue.  Notably, we do not observe detectable levels of 
nuclear IKKβ.  To determine whether nuclear IKKα and GSK-3 mediate constitutive NF-κB 
activity at the transcription complex level in pancreatic cancer cells, chromatin 
immunoprecipitation should be performed to detect recruitment of these kinases to known 
NF-κB target promoters (i.e. IκBα, Bcl-XL, and cIAP2).  Future studies should also ascertain 
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the requirement for nuclear IKKα and GSK-3 in mediating constitutive NF-κB activity.  
Therefore, stable IKKα and GSK-3 null pancreatic cancer cells should be reconstituted with 
mutant IKKα and GSK-3 that lack a functional NLS.  These reconstitution experiments 
would address whether these kinases are required for recruitment of NF-κB to target 
promoter.  Moreover, these studies would also determine the requirement of IKKα and GSK-
3 for transcriptionally active histone modifications (i.e. phosphorylation of histone H3 as 
serine 10).  Overall, the experiments described above may implicate a dual role for GSK-3 
and IKKα in mediating constitutive NF-κB activity at the cytoplasmic and transcriptional 
complex level in pancreatic cancer cells.   
     (4) Are the activities of GSK-3 and TAK1 required for pancreatic cancer 
progression in vivo? 
The previous chapters have demonstrated that GSK-3 and TAK1 play a key role in mediating 
constitutive pro-survival NF-κB activity in pancreatic cancer cells.  These data implicate 
GSK-3 and TAK1 as potential therapeutic targets for pancreatic cancer.  In order to pursue 
this therapeutic strategy, further evidence is needed to establish the requirement of these 
kinases within animal models.  Furthermore, additional studies are needed to explore the 
efficacy of GSK-3 and TAK1 inhibition on pancreatic cancer progression in vivo.  GSK-3 
inhibition (120 mg/ kg AR-A014418; every 12 hours for 2 days) was reported to suppress the 
tumor growth of an established CAPAN2 xenograft model (Ougolkov, Fernandez-Zapico et 
al. 2006).  However, xenograft models do not mimic the unique tumor microenvironment 
necessary for pancreatic cancer progression.  Therefore, alternative pancreatic cancer mouse 
models are needed to address the roles GSK-3 and TAK1 play during tumor progression.  
Concomitant endogenous expression of KrasG12D and Trp53R172H in mouse pancreas 
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progenitor cells leads to accelerated pancreatic cancer development (Hingorani, Wang et al. 
2005).  Importantly, this animal model mimics human pancreatic cancer progression with 
similar histological, clinical, and genetic phenotypes (Hingorani, Wang et al. 2005).  Future 
studies should utilize GSK-3 (AR-A014418) and TAK1 (5Z-7 oxozeanol) inhibitors to 
determine the requirements of these kinases for pancreatic cancer progression and overall 
survival. More importantly, the potential off-target effects these drugs may have on 
surrounding normal tissue should also be examined.  Alternatively, studies should explore 
whether targeted depletion of GSK-3α, GSK-3β, or TAK1 in pancreas progenitor cells could 
attenuate pancreatic cancer progression within the KrasG12D, Trp53R172H animal model.  
Ultimately, the experiments described above will provide the first steps necessary to 
implement the development of GSK-3 and TAK1 targeted therapies for pancreatic cancer, 
and their use in future clinical trials.   
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